
<!DOCTYPE html>
<html lang="en" >
    <head >

        <meta charset="UTF-8" />
        <meta http-equiv="X-UA-Compatible" content="IE=edge" />
        <meta name="HandheldFriendly" content="True" />
        <meta name="MobileOptimized" content="320" />
        <meta name="viewport" content="width=device-width, initial-scale=1.0" />

        
        

        
        
  <link rel="stylesheet" href="/static/assets/base_style-CPPDhfna.css" />
<script type="module" crossorigin="" src="/static/assets/base_style-BepKMsUl.js"></script>

  <link rel="stylesheet" href="/static/assets/article_style-DUfI1jZp.css" />
<link rel="stylesheet" href="/static/assets/style-BOrsu84o.css" />
<script type="module" crossorigin="" src="/static/assets/article_style-D3wJHomh.js"></script>

  
  
    <style>
  
  
  @media screen and (min-width: 64em) {
    div.pmc-wm {
      background: repeat-y;
      background-image: url("data:image/svg+xml,%3Csvg xmlns='http://www.w3.org/2000/svg' width='20' height='350' xmlns:xlink='http://www.w3.org/1999/xlink'%3E%3Cdefs%3E%3Cfilter x='-.02' y='0' width='1.05' height='1' id='c'%3E%3CfeFlood flood-color='%23FFF'/%3E%3CfeComposite in='SourceGraphic'/%3E%3C/filter%3E%3Ctext id='b' font-family='Helvetica' font-size='11pt' style='opacity:1;fill:%23005ea2;stroke:none;text-anchor:middle' x='175' y='14'%3E%3C/text%3E%3Cpath id='a' style='fill:%23005ea2' d='M0 8h350v3H0z'/%3E%3C/defs%3E%3Cuse xlink:href='%23a' transform='rotate(90 10 10)'/%3E%3Cuse xlink:href='%23b' transform='rotate(90 10 10)' filter='url(%23c)'/%3E%3C/svg%3E");
      padding-left: 3rem;
    }
  }
</style>

  



        
            <link rel="apple-touch-icon"
                  sizes="180x180"
                  href="/static/img/favicons/apple-touch-icon.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="48x48"
                  href="/static/img/favicons/favicon-48x48.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="32x32"
                  href="/static/img/favicons/favicon-32x32.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="16x16"
                  href="/static/img/favicons/favicon-16x16.png" />
            <link rel="manifest" href="/static/img/favicons/site.webmanifest" />
            <link rel="mask-icon"
                  href="/static/img/favicons/safari-pinned-tab.svg"
                  color="#0071bc" />
            <meta name="msapplication-config"
                  content="/static/img/favicons/browserconfig.xml" />
            <meta name="theme-color" content="#ffffff" />
        

        <title>
            Trends in adverse drug reaction reporting in eight selected countries after the implementation of new pharmacovigilance regulation in 2012: a joinpoint regression analysis - PMC
        </title>

        
        
  
  <!-- Logging params: Pinger defaults -->
<meta name="ncbi_app" content="cloudpmc-viewer" />
<meta name="ncbi_db" content="pmc" />
<meta name="ncbi_phid" content="18DE23DD930AEA030023DD0048B1D85F.m_1" />
<meta name="ncbi_pinger_stat_url" content="https://pmc.ncbi.nlm.nih.gov/stat" />
<!-- Logging params: Pinger custom -->
<meta name="ncbi_pdid" content="article" />
  
    <link rel="preconnect" href="https://www.google-analytics.com" />

    
        <link rel="preconnect" href="https://cdn.ncbi.nlm.nih.gov" />
    

    <!-- Include USWDS Init Script -->
    <script src="/static/assets/uswds-init.js"></script>


    <meta name="ncbi_domain" content="springeropen">
<meta name="ncbi_type" content="fulltext">
<meta name="ncbi_pcid" content="journal">
<meta name="ncbi_feature" content="associated_data">
<link rel="canonical" href="https://pmc.ncbi.nlm.nih.gov/articles/PMC12398448/">
<meta name="robots" content="INDEX,NOFOLLOW,NOARCHIVE">
<meta name="citation_journal_title" content="European Journal of Clinical Pharmacology">
<meta name="citation_title" content="Trends in adverse drug reaction reporting in eight selected countries after the implementation of new pharmacovigilance regulation in 2012: a joinpoint regression analysis">
<meta name="citation_author" content="Greta Masiliūnienė">
<meta name="citation_author_institution" content="Institute of Physiology and Pharmacology, Faculty of Medicine, Medical Academy, Lithuanian University of Health Sciences, A. Mickevičiaus 9, 44307 Kaunas, Lithuania">
<meta name="citation_author" content="Edgaras Stankevičius">
<meta name="citation_author_institution" content="Institute of Physiology and Pharmacology, Faculty of Medicine, Medical Academy, Lithuanian University of Health Sciences, A. Mickevičiaus 9, 44307 Kaunas, Lithuania">
<meta name="citation_author" content="Edmundas Kaduševičius">
<meta name="citation_author_institution" content="Institute of Physiology and Pharmacology, Faculty of Medicine, Medical Academy, Lithuanian University of Health Sciences, A. Mickevičiaus 9, 44307 Kaunas, Lithuania">
<meta name="citation_publication_date" content="2025 Jun 17">
<meta name="citation_volume" content="81">
<meta name="citation_issue" content="9">
<meta name="citation_firstpage" content="1287">
<meta name="citation_doi" content="10.1007/s00228-025-03862-2">
<meta name="citation_pmid" content="40528085">
<meta name="citation_abstract_html_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12398448/">
<meta name="citation_fulltext_html_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12398448/">
<meta name="citation_pdf_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12398448/pdf/228_2025_Article_3862.pdf">
<meta name="description" content="Underreporting of adverse drug reactions (ADRs) remains to be a challenge in modern health care. Major reforms in the EU pharmacovigilance system in 2012 introduced the legal basis for consumers to report suspected ADRs. This study was designed to ...">
<meta name="og:title" content="Trends in adverse drug reaction reporting in eight selected countries after the implementation of new pharmacovigilance regulation in 2012: a joinpoint regression analysis">
<meta name="og:type" content="article">
<meta name="og:site_name" content="PubMed Central (PMC)">
<meta name="og:description" content="Underreporting of adverse drug reactions (ADRs) remains to be a challenge in modern health care. Major reforms in the EU pharmacovigilance system in 2012 introduced the legal basis for consumers to report suspected ADRs. This study was designed to ...">
<meta name="og:url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12398448/">
<meta name="og:image" content="https://cdn.ncbi.nlm.nih.gov/pmc/cms/images/pmc-card-share.jpg?_=0">
<meta name="twitter:card" content="summary_large_image">
<meta name="twitter:site" content="@ncbi">
    
    

    </head>
    <body >
        
    <a class="usa-skipnav " href="#main-content">
      Skip to main content
    </a>


        
            

<section class="usa-banner " aria-label="Official website of the United States government" >
    <div class="usa-accordion">
        <header class="usa-banner__header">
            <div class="usa-banner__inner">
                <div class="grid-col-auto">
                    <img aria-hidden="true"
                         class="usa-banner__header-flag"
                         src="/static/img/us_flag.svg"
                         alt="" />
                </div>

                <div class="grid-col-fill tablet:grid-col-auto" aria-hidden="true">
                    <p class="usa-banner__header-text">
                        An official website of the United States government
                    </p>
                    <span class="usa-banner__header-action">Here's how you know</span>
                </div>

                



















    
        <button
            type="button"
        
    
    class="usa-accordion__button usa-banner__button
           

           
               
               
               
               
            

           
           
           
           "
    aria-expanded="false"
    aria-controls="gov-banner-default"
    
    data-testid="storybook-django-banner"
    
    >
    
        

        
                    <span class="usa-banner__button-text">Here's how you know</span>
                

        
    
        
            </button>
        


            </div>
        </header>

        <div class="usa-banner__content usa-accordion__content"
             id="gov-banner-default"
             hidden>
            <div class="grid-row grid-gap-lg">
                <div class="usa-banner__guidance tablet:grid-col-6">
                    <img class="usa-banner__icon usa-media-block__img"
                         src="/static/img/icon-dot-gov.svg"
                         alt=""
                         aria-hidden="true" />
                    <div class="usa-media-block__body">
                        <p>
                            <strong>Official websites use .gov</strong>
                            <br />
                            A
                            <strong>.gov</strong> website belongs to an official
                            government organization in the United States.
                        </p>
                    </div>
                </div>

                <div class="usa-banner__guidance tablet:grid-col-6">
                    <img class="usa-banner__icon usa-media-block__img"
                         src="/static/img/icon-https.svg"
                         alt=""
                         aria-hidden="true" />

                    <div class="usa-media-block__body">
                        <p>
                            <strong>Secure .gov websites use HTTPS</strong>
                            <br />
                            A <strong>lock</strong> (
                            <span class="icon-lock">
                                <svg xmlns="http://www.w3.org/2000/svg"
                                     width="52"
                                     height="64"
                                     viewBox="0 0 52 64"
                                     class="usa-banner__lock-image"
                                     role="graphics-symbol"
                                     aria-labelledby="banner-lock-description"
                                     focusable="false">
                                    <title id="banner-lock-title">Lock</title>
                                    <desc id="banner-lock-description">
                                    Locked padlock icon
                                    </desc>
                                    <path fill="#000000"
                                          fill-rule="evenodd"
                                          d="M26 0c10.493 0 19 8.507 19 19v9h3a4 4 0 0 1 4 4v28a4 4 0 0 1-4 4H4a4 4 0 0 1-4-4V32a4 4 0 0 1 4-4h3v-9C7 8.507 15.507 0 26 0zm0 8c-5.979 0-10.843 4.77-10.996 10.712L15 19v9h22v-9c0-6.075-4.925-11-11-11z" />
                                </svg>
</span>) or <strong>https://</strong> means you've safely
                                connected to the .gov website. Share sensitive
                                information only on official, secure websites.
                            </p>
                        </div>
                    </div>
                </div>
            </div>
        </div>
    </section>

        

        
    
    
    

<div class="usa-overlay">
</div>



<header class="usa-header usa-header--extended usa-header--wide" data-header data-testid="header"    >
    <div class="ncbi-header">
        <div class="ncbi-header__container">
            <a class="ncbi-header__logo-container"
               href="https://www.ncbi.nlm.nih.gov/">
                <img alt="NCBI home page"
                     class="ncbi-header__logo-image"
                     src="/static/img/ncbi-logos/nih-nlm-ncbi--white.svg"
                     width="410"
                     height="100" />
            </a>

            <!-- Mobile menu hamburger button -->
            



















    
        <button
            type="button"
        
    
    class="usa-menu-btn ncbi-header__hamburger-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    aria-label="Show menu"
    data-testid="navMenuButton"
    
    >
    
        

        
                <svg aria-hidden="true"
                     class="ncbi-hamburger-icon"
                     fill="none"
                     focusable="false"
                     height="21"
                     viewBox="0 0 31 21"
                     width="31"
                     xmlns="http://www.w3.org/2000/svg">
                    <path clip-rule="evenodd"
                          d="M0.125 20.75H30.875V17.3333H0.125V20.75ZM0.125 12.2083H30.875V8.79167H0.125V12.2083ZM0.125 0.25V3.66667H30.875V0.25H0.125Z"
                          fill="#F1F1F1"
                          fill-rule="evenodd" />
                </svg>
            

        
    
        
            </button>
        



            
                <!-- Desktop buttons-->
                <div class="ncbi-header__desktop-buttons">
                    
                        <!-- Desktop search button -->
                        



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--unstyled ncbi-header__desktop-button
           "
    aria-expanded="false"
    aria-controls="search-field-desktop-navigation"
    aria-label="Show search overlay"
    data-testid="toggleSearchPanelButton"
    data-toggle-search-panel-button
    >
    
        

        
                            



    <svg class="usa-icon " role="graphics-symbol" aria-hidden="true" >
        
        <use xlink:href="/static/img/sprite.svg#search" />
    </svg>


                            Search
                        

        
    
        
            </button>
        


                    

                    <!-- Desktop login dropdown -->
                    
                        <div class="ncbi-header__login-dropdown">
                            



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--unstyled ncbi-header__desktop-button ncbi-header__login-dropdown-button
           "
    aria-expanded="false"
    aria-controls="login-dropdown-menu"
    aria-label="Show login menu"
    data-testid="toggleLoginMenuDropdown"
    data-desktop-login-button
    >
    
        

        
                                



    <svg class="usa-icon " role="graphics-symbol" aria-hidden="true" >
        
        <use xlink:href="/static/img/sprite.svg#person" />
    </svg>



                                <span data-login-dropdown-text>Log in</span>

                                <!-- Dropdown icon pointing up -->
                                



    <svg class="usa-icon ncbi-header__login-dropdown-icon ncbi-header__login-dropdown-icon--expand-less ncbi-header__login-dropdown-icon--hidden" role="graphics-symbol" aria-hidden="true" data-login-dropdown-up-arrow>
        
        <use xlink:href="/static/img/sprite.svg#expand_less" />
    </svg>



                                <!-- Dropdown icon pointing down -->
                                



    <svg class="usa-icon ncbi-header__login-dropdown-icon ncbi-header__login-dropdown-icon--expand-more ncbi-header__login-dropdown-icon--hidden" role="graphics-symbol" aria-hidden="true" data-login-dropdown-down-arrow>
        
        <use xlink:href="/static/img/sprite.svg#expand_more" />
    </svg>


                            

        
    
        
            </button>
        



                            <!-- Login dropdown menu -->
                            <ul class="usa-nav__submenu ncbi-header__login-dropdown-menu"
                                id="login-dropdown-menu"
                                data-desktop-login-menu-dropdown
                                hidden>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/" class="usa-link  "  >
        

        
            Dashboard
        

        
    </a>


                                    </li>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/" class="usa-link  "  >
        

        
            Publications
        

        
    </a>


                                    </li>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        









    <a href="https://www.ncbi.nlm.nih.gov/account/settings/" class="usa-link  "  >
        

        
            Account settings
        

        
    </a>


                                    </li>
                                
                                <li class="usa-nav__submenu-item">
                                    



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--outline ncbi-header__login-dropdown-logout-button
           "
    
    
    
    data-testid="desktopLogoutButton"
    data-desktop-logout-button
    >
    
        

        Log out

        
    
        
            </button>
        


                                </li>
                            </ul>
                        </div>
                    
                </div>
            
        </div>
    </div>

    <!-- Search panel -->
    
        <div class="ncbi-search-panel ncbi--show-only-at-desktop"
             data-header-search-panel
             hidden>
            <div class="ncbi-search-panel__container">
                <form action="https://www.ncbi.nlm.nih.gov/search/all/"
                      
                      autocomplete="off"
                      class="usa-search usa-search--big ncbi-search-panel__form"
                      data-testid="desktop-navigation-search-form"
                      method="GET"
                      role="search">
                    <label class="usa-sr-only" for="search-field-desktop-navigation">
                        Search…
                    </label>
                    <input class="usa-input"
                           id="search-field-desktop-navigation"
                           name="term"
                           
                               placeholder="Search NCBI"
                           
                           type="search"
                           value="" />
                    



















    
        <button
            type="submit"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    
    
    
    >
    
        

        
                        <span class="usa-search__submit-text">
                            Search NCBI
                        </span>
                    

        
    
        
            </button>
        


                </form>

                
            </div>
        </div>
    

    <nav aria-label="Primary navigation" class="usa-nav">
        <p class="usa-sr-only" id="primary-navigation-sr-only-title">
            Primary site navigation
        </p>

        <!-- Mobile menu close button -->
        



















    
        <button
            type="button"
        
    
    class="usa-nav__close ncbi-nav__close-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    aria-label="Close navigation menu"
    data-testid="navCloseButton"
    
    >
    
        

        
            <img src="/static/img/usa-icons/close.svg" alt="Close" />
        

        
    
        
            </button>
        



        
            <!-- Mobile search component -->
            <form class="usa-search usa-search--small ncbi--hide-at-desktop margin-top-6"
                  action="https://www.ncbi.nlm.nih.gov/search/all/"
                  
                  autocomplete="off"
                  data-testid="mobile-navigation-search-form"
                  method="GET"
                  role="search">
                <label class="usa-sr-only" for="search-field-mobile-navigation">
                    Search
                </label>

                <input class="usa-input"
                       id="search-field-mobile-navigation"
                       type="search"
                       
                           placeholder="Search NCBI"
                       
                       name="term" />

                



















    
        <button
            type="submit"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    
    
    
    >
    
        

        
                    <!-- This SVG should be kept inline and not replaced with a link to the icon as otherwise it will render in the wrong color -->
                    <img src="data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIGhlaWdodD0iMjQiIHZpZXdCb3g9IjAgMCAyNCAyNCIgd2lkdGg9IjI0Ij48cGF0aCBkPSJNMCAwaDI0djI0SDB6IiBmaWxsPSJub25lIi8+PHBhdGggZmlsbD0iI2ZmZiIgZD0iTTE1LjUgMTRoLS43OWwtLjI4LS4yN0E2LjQ3MSA2LjQ3MSAwIDAgMCAxNiA5LjUgNi41IDYuNSAwIDEgMCA5LjUgMTZjMS42MSAwIDMuMDktLjU5IDQuMjMtMS41N2wuMjcuMjh2Ljc5bDUgNC45OUwyMC40OSAxOWwtNC45OS01em0tNiAwQzcuMDEgMTQgNSAxMS45OSA1IDkuNVM3LjAxIDUgOS41IDUgMTQgNy4wMSAxNCA5LjUgMTEuOTkgMTQgOS41IDE0eiIvPjwvc3ZnPg=="
                         class="usa-search__submit-icon"
                         alt="Search" />
                

        
    
        
            </button>
        


            </form>

            
        

        <!-- Primary navigation menu items -->
        <!-- This usa-nav__inner wrapper is required to correctly style the navigation items on Desktop -->
        

        
            <div class="ncbi-nav__mobile-login-menu ncbi--hide-at-desktop"
                 data-mobile-login-menu
                 hidden>
                <p class="ncbi-nav__mobile-login-menu-status">
                    Logged in as:
                    <strong class="ncbi-nav__mobile-login-menu-email"
                            data-mobile-login-email-text></strong>
                </p>
                <ul class="usa-nav__primary usa-accordion">
                    
                        <li class="usa-nav__primary-item">
                            









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/" class="usa-link  "  >
        

        
            Dashboard
        

        
    </a>


                        </li>
                    
                        <li class="usa-nav__primary-item">
                            









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/" class="usa-link  "  >
        

        
            Publications
        

        
    </a>


                        </li>
                    
                        <li class="usa-nav__primary-item">
                            









    <a href="https://www.ncbi.nlm.nih.gov/account/settings/" class="usa-link  "  >
        

        
            Account settings
        

        
    </a>


                        </li>
                    
                </ul>
            </div>
        

        



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           ncbi-nav__mobile-login-button ncbi--hide-at-desktop
           "
    
    
    
    data-testid="mobileLoginButton"
    data-mobile-login-button
    >
    
        

        Log in

        
    
        
            </button>
        


    </nav>
</header>

    
    
        

<section class="pmc-header pmc-header--basic" aria-label="PMC Header with search box">
    <div class="pmc-nav-container">
        <div class="pmc-header__bar">
           <div class="pmc-header__logo">
               <a href="/" title="Home" aria-label="PMC Home"></a>
           </div>
            <button
                    type="button"
                    class="usa-button usa-button--unstyled pmc-header__search__button"
                    aria-label="Open search"
                    data-ga-category="search"
                    data-ga-action="PMC"
                    data-ga-label="pmc_search_panel_mobile"
            >
                <svg class="usa-icon width-4 height-4 pmc-icon__open" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#search"></use>
                </svg>
                <svg class="usa-icon width-4 height-4 pmc-icon__close" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#close"></use>
                </svg>
            </button>
        </div>
        <div class="pmc-header__search">
            


<form class="usa-search usa-search--extra usa-search--article-right-column  pmc-header__search__form" id="pmc-search-form" autocomplete="off" role="search">
<label class="usa-sr-only" for="pmc-search">Search PMC Full-Text Archive</label>
<span class="autoComplete_wrapper flex-1">
<input class="usa-input width-full maxw-none" required="required" placeholder="Search PMC Full-Text Archive" id="pmc-search"  type="search" name="term" data-autocomplete-url="https://pmc.ncbi.nlm.nih.gov/autocomp/search/autocomp/"/>
</span>
<button
class="usa-button"
type="submit"
formaction="https://pmc.ncbi.nlm.nih.gov/search/"
data-ga-category="search"
data-ga-action="PMC"
data-ga-label="PMC_search_button"
>
<span class="usa-search__submit-text">Search in PMC</span>
<img
src="/static/img/usa-icons-bg/search--white.svg"
class="usa-search__submit-icon"
alt="Search"
/>
</button>
</form>
            <div class="display-flex flex-column tablet:flex-row tablet:flex-justify flex-justify-center flex-align-center width-full desktop:maxw-44">
                <ul class="pmc-header__search__menu">
                    <li>
                        
                            <a class="usa-link" href="/journals/" data-ga-action="featured_link" data-ga-label="journal list">
                                Journal List
                            </a>
                        
                    </li>
                    <li>
                        
                            <a class="usa-link" href="/about/userguide/" data-ga-action="featured_link"
                            data-ga-label="user guide">
                                User Guide
                            </a>
                        
                    </li>
                </ul>
            </div>
        </div>
    </div>
</section>

    


        
        

       
  <div class="usa-section padding-top-0 desktop:padding-top-6 pmc-article-section" data-article-db="pmc" data-article-id="12398448">

    

   



<div class="grid-container pmc-actions-bar" aria-label="Actions bar" role="complementary">
    <div class="grid-row">
        <div class="grid-col-fill display-flex">
             <div class="display-flex">
                <ul class="usa-list usa-list--unstyled usa-list--horizontal">
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex mob">
                        <button
                                type="button"
                                class="usa-button pmc-sidenav__container__open usa-button--unstyled width-auto display-flex"
                                aria-label="Open resources"
                                data-extra-class="is-visible-resources"
                                data-ga-category="resources_accordion"
                                data-ga-action="click"
                                data-ga-label="mobile_icon"
                        >
                            <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                <use xlink:href="/static/img/sprite.svg#more_vert"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex mob">
                        <a
                                href="https://doi.org/10.1007/s00228-025-03862-2"
                                class="usa-link display-flex usa-tooltip"
                                role="button"
                                target="_blank"
                                rel="noreferrer noopener"
                                title="View on publisher site"
                                data-position="bottom"
                                aria-label="View on publisher site"
                                data-ga-category="actions"
                                data-ga-action="click"
                                data-ga-label="publisher_link_mobile"
                        >
                                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                    <use xlink:href="/static/img/sprite.svg#launch"></use>
                                </svg>
                        </a>
                    </li>
                    
                    
                        <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                             <a
                                     href="pdf/228_2025_Article_3862.pdf"
                                     class="usa-link display-flex usa-tooltip"
                                     role="button"
                                     title="Download PDF"
                                     data-position="bottom"
                                     aria-label="Download PDF"
                                     data-ga-category="actions"
                                     data-ga-action="click"
                                     data-ga-label="pdf_download_mobile"
                             >
                                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                    <use xlink:href="/static/img/sprite.svg#file_download"></use>
                                </svg>
                            </a>
                        </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                        <button
                            class="usa-button usa-button--unstyled  usa-tooltip collections-dialog-trigger collections-button display-flex collections-button-empty"
                            title="Add to Collections"
                            data-position="bottom"
                            aria-label="Save article in MyNCBI collections."
                            data-ga-category="actions"
                            data-ga-action="click"
                            data-ga-label="collections_button_mobile"
                            data-collections-open-dialog-enabled="false"
                            data-collections-open-dialog-url="https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpmc.ncbi.nlm.nih.gov%2Farticles%2FPMC12398448%2F%23open-collections-dialog"
                            data-in-collections="false"
                        >
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-full" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-full.svg#icon"></use>
                            </svg>
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-empty.svg#icon"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                        <button role="button" class="usa-button usa-button--unstyled usa-tooltip citation-dialog-trigger display-flex"
                            aria-label="Open dialog with citation text in different styles"
                            title="Cite"
                            data-position="bottom"
                            data-ga-category="actions"
                            data-ga-action="open"
                            data-ga-label="cite_mobile"
                            data-all-citations-url="/resources/citations/12398448/"
                            data-citation-style="nlm"
                            data-download-format-link="/resources/citations/12398448/export/"
                        >
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/sprite.svg#format_quote"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="pmc-permalink display-flex" >
                         <button
                                 type="button"
                                 title="Permalink"
                                 data-position="bottom"
                                 class="usa-button usa-button--unstyled display-flex usa-tooltip"
                                 aria-label="Show article permalink"
                                 aria-expanded="false"
                                 aria-haspopup="true"
                                 data-ga-category="actions"
                                 data-ga-action="open"
                                 data-ga-label="permalink_mobile"
                         >
                            <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                <use xlink:href="/static/img/sprite.svg#share"></use>
                            </svg>
                        </button>
                        

<div class="pmc-permalink__dropdown" hidden>
    <div class="pmc-permalink__dropdown__container">
          <h2 class="usa-modal__heading margin-top-0 margin-bottom-2 text-uppercase font-sans-xs">PERMALINK</h2>
          <div class="pmc-permalink__dropdown__content">
              <input type="text" class="usa-input" value="https://pmc.ncbi.nlm.nih.gov/articles/PMC12398448/" aria-label="Article permalink">
              <button class="usa-button display-inline-flex pmc-permalink__dropdown__copy__btn margin-right-0" title="Copy article permalink" data-ga-category="save_share" data-ga-action="link" data-ga-label="copy_link">
                  <svg class="usa-icon" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#content_copy"></use>
                  </svg>
                  <span class="margin-left-1">Copy</span>
              </button>
          </div>
    </div>
</div>
                    </li>
                </ul>
            </div>
            <button
                    type="button"
                    class="usa-button pmc-sidenav__container__open usa-button--unstyled width-auto display-flex"
                    aria-label="Open article navigation"
                    data-extra-class="is-visible-in-page"
                    data-ga-category="actions"
                    data-ga-action="open"
                    data-ga-label="article_nav_mobile"
            >
                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#list"></use>
                </svg>
            </button>
        </div>
    </div>
</div>
    <div class="grid-container desktop:padding-left-6">
      <div id="article-container" class="grid-row grid-gap">
        <div class="grid-col-12 desktop:grid-col-8 order-2 pmc-layout__content">
            <div class="grid-container padding-left-0 padding-right-0">
                <div class="grid-row desktop:margin-left-neg-6">
                    <div class="grid-col-12">
                        <div class="pmc-layout__disclaimer" role="complementary" aria-label="Disclaimer note">
    As a library, NLM provides access to scientific literature. Inclusion in an NLM database does not imply endorsement of, or agreement with,
    the contents by NLM or the National Institutes of Health.<br/>
    Learn more:
    <a class="usa-link" data-ga-category="Link click" data-ga-action="Disclaimer" data-ga-label="New disclaimer box" href="/about/disclaimer/">PMC Disclaimer</a>
    |
    <a class="usa-link" data-ga-category="Link click" data-ga-action="PMC Copyright Notice" data-ga-label="New disclaimer box" href="/about/copyright/">
        PMC Copyright Notice
    </a>
</div>
                    </div>
                </div>
                <div class="grid-row pmc-wm desktop:margin-left-neg-6">
                    <!-- Main content -->
                    <main
                      id="main-content"
                      class="usa-layout-docs__main usa-layout-docs grid-col-12 pmc-layout pmc-prose padding-0"
                    >

                      
                        <section class="pmc-journal-banner text-center line-height-none" aria-label="Journal banner"><img src="https://cdn.ncbi.nlm.nih.gov/pmc/banners/logo-springeropen.png" alt="Springer logo" usemap="#pmc-banner-imagemap" width="500" height="75"><map name="pmc-banner-imagemap"><area alt="Link to Springer" title="Link to Springer" shape="default" href="https://doi.org/10.1007/s00228-025-03862-2" target="_blank" rel="noopener noreferrer"></map></section><article lang="en"><section aria-label="Article citation and metadata"><section class="pmc-layout__citation font-secondary font-xs"><div>
<div class="display-inline-block"><button type="button" class="cursor-pointer text-no-underline bg-transparent border-0 padding-0 text-left margin-0 text-normal text-primary" aria-controls="journal_context_menu">Eur J Clin Pharmacol</button></div>. 2025 Jun 17;81(9):1287–1299. doi: <a href="https://doi.org/10.1007/s00228-025-03862-2" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">10.1007/s00228-025-03862-2</a>
</div>
<nav id="journal_context_menu" hidden="hidden"><ul class="menu-list font-family-ui" role="menu">
<li role="presentation"><a href="https://pmc.ncbi.nlm.nih.gov/search/?term=%22Eur%20J%20Clin%20Pharmacol%22%5Bjour%5D" class="usa-link" role="menuitem">Search in PMC</a></li>
<li role="presentation"><a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Eur%20J%20Clin%20Pharmacol%22%5Bjour%5D" lang="en" class="usa-link" role="menuitem">Search in PubMed</a></li>
<li role="presentation"><a href="https://www.ncbi.nlm.nih.gov/nlmcatalog?term=%22Eur%20J%20Clin%20Pharmacol%22%5BTitle%20Abbreviation%5D" class="usa-link" role="menuitem">View in NLM Catalog</a></li>
<li role="presentation"><a href="?term=%22Eur%20J%20Clin%20Pharmacol%22%5Bjour%5D" class="usa-link" role="menuitem" data-add-to-search="true">Add to search</a></li>
</ul></nav></section><section class="front-matter"><div class="ameta p font-secondary font-xs">
<hgroup><h1>Trends in adverse drug reaction reporting in eight selected countries after the implementation of new pharmacovigilance regulation in 2012: a joinpoint regression analysis</h1></hgroup><div class="cg p">
<a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Masili%C5%ABnien%C4%97%20G%22%5BAuthor%5D" class="usa-link" aria-describedby="id1"><span class="name western">Greta Masiliūnienė</span></a><div hidden="hidden" id="id1">
<h3><span class="name western">Greta Masiliūnienė</span></h3>
<div class="p">
<sup>1</sup>Institute of Physiology and Pharmacology, Faculty of Medicine, Medical Academy, Lithuanian University of Health Sciences, A. Mickevičiaus 9, 44307 Kaunas, Lithuania </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Masili%C5%ABnien%C4%97%20G%22%5BAuthor%5D" class="usa-link"><span class="name western">Greta Masiliūnienė</span></a>
</div>
</div>
<sup>1,</sup><sup>✉</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Stankevi%C4%8Dius%20E%22%5BAuthor%5D" class="usa-link" aria-describedby="id2"><span class="name western">Edgaras Stankevičius</span></a><div hidden="hidden" id="id2">
<h3><span class="name western">Edgaras Stankevičius</span></h3>
<div class="p">
<sup>1</sup>Institute of Physiology and Pharmacology, Faculty of Medicine, Medical Academy, Lithuanian University of Health Sciences, A. Mickevičiaus 9, 44307 Kaunas, Lithuania </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Stankevi%C4%8Dius%20E%22%5BAuthor%5D" class="usa-link"><span class="name western">Edgaras Stankevičius</span></a>
</div>
</div>
<sup>1</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Kadu%C5%A1evi%C4%8Dius%20E%22%5BAuthor%5D" class="usa-link" aria-describedby="id3"><span class="name western">Edmundas Kaduševičius</span></a><div hidden="hidden" id="id3">
<h3><span class="name western">Edmundas Kaduševičius</span></h3>
<div class="p">
<sup>1</sup>Institute of Physiology and Pharmacology, Faculty of Medicine, Medical Academy, Lithuanian University of Health Sciences, A. Mickevičiaus 9, 44307 Kaunas, Lithuania </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Kadu%C5%A1evi%C4%8Dius%20E%22%5BAuthor%5D" class="usa-link"><span class="name western">Edmundas Kaduševičius</span></a>
</div>
</div>
<sup>1</sup>
</div>
<ul class="d-buttons inline-list">
<li><button class="d-button" aria-controls="aip_a" aria-expanded="false">Author information</button></li>
<li><button class="d-button" aria-controls="anp_a" aria-expanded="false">Article notes</button></li>
<li><button class="d-button" aria-controls="clp_a" aria-expanded="false">Copyright and License information</button></li>
</ul>
<div class="d-panels font-secondary-light">
<div id="aip_a" class="d-panel p" style="display: none">
<div class="p" id="Aff1">
<sup>1</sup>Institute of Physiology and Pharmacology, Faculty of Medicine, Medical Academy, Lithuanian University of Health Sciences, A. Mickevičiaus 9, 44307 Kaunas, Lithuania </div>
<div class="author-notes p"><div class="fn" id="_fncrsp93pmc__">
<sup>✉</sup><p class="display-inline">Corresponding author.</p>
</div></div>
</div>
<div id="anp_a" class="d-panel p" style="display: none"><div class="notes p"><section id="historyarticle-meta1" class="history"><p>Received 2024 Oct 22; Accepted 2025 Jun 2; Issue date 2025.</p></section></div></div>
<div id="clp_a" class="d-panel p" style="display: none">
<div>© The Author(s) 2025</div>
<p><strong>Open Access</strong> This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <a href="https://creativecommons.org/licenses/by-nc-nd/4.0/" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">http://creativecommons.org/licenses/by-nc-nd/4.0/</a>.</p>
<div class="p"><a href="/about/copyright/" class="usa-link">PMC Copyright notice</a></div>
</div>
</div>
<div>PMCID: PMC12398448  PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/40528085/" class="usa-link">40528085</a>
</div>
</div></section></section><section aria-label="Article content"><section class="body main-article-body"><section class="abstract" id="Abs1"><h2>Abstract</h2>
<section id="sec1"><h3 class="pmc_sec_title">Background and purpose</h3>
<p id="Par1">Underreporting of adverse drug reactions (ADRs) remains to be a challenge in modern health care. Major reforms in the EU pharmacovigilance system in 2012 introduced the legal basis for consumers to report suspected ADRs. This study was designed to determine trends in overall ADR reporting, the ratio of health care professional (HCP)-to-consumer ADR reporting, and the ratio of serious-to-nonserious ADR reporting for an 11-year period in the selected non-EU and EU countries that had implemented systems for consumers’ reporting before the 2012 EU pharmacovigilance legislation and those that did not have.</p></section><section id="sec2"><h3 class="pmc_sec_title">Materials and methods</h3>
<p id="Par2">The national competent authorities of 15 countries (11 EU countries, former EU member the UK, Australia, Canada, and the USA) were contacted via e-mail and asked to provide the total number of ADR reports, numbers of ADRs reported by consumers and HCPs, numbers of serious and nonserious ADRs, and top 5 medication groups causing ADRs by the Anatomical Therapeutic Chemical (ATC) classification system during the period of 2012–2022. Eight countries, namely Belgium, Canada, Finland, Lithuania, the Netherlands, Portugal, Sweden, and the UK, responded and provided the data. The trends of ADR reporting were evaluated with the joinpoint regression analysis method. The annual percent change (APC) and the average annual percent change (AAPC) were estimated.</p></section><section id="sec3"><h3 class="pmc_sec_title">Results</h3>
<p id="Par3">Over the study period, the overall rates of ADR reporting increased significantly in all the countries except for Belgium, with the greatest AAPC being in Lithuania (AAPC of 32.34) and the lowest, in Canada (AAPC of 10.3). The ratios of HCP-to-consumer ADR reporting were significantly decreasing in all the countries (AAPC range, –43.7 to –24.9) except for Canada where an opposite significant trend toward an increasing HCP reporting rate (AAPC of 3.9) for 2012–2020 was observed. The ratios of serious-to-nonserious ADR reporting were significantly decreasing in more than half of the countries, namely Canada, Finland, Lithuania, the Netherlands, and Portugal, with the greatest negative AAPC being in Lithuania (AAPC of –32.9) and the smallest, in Canada (AAPC of –6.8). Vaccines (J07), immunosuppressants (L04), antineoplastic agents (L01), antibacterials for systemic use (J01), and antithrombotic agents (B01) were found to be the top 5 most frequently reported medications.</p></section><section id="sec4"><h3 class="pmc_sec_title">Conclusions</h3>
<p id="Par4">This study shows the significant upward trends in overall ADR reporting not only in the countries that implemented consumer ADR reporting systems after the 2012 EU pharmacovigilance legislation but also in countries that had consumer reporting systems before 2012. Moreover, significant downward trends in the ratios of HCP-to-consumer ADR reporting were documented for all EU countries, confirming increasing consumers’ involvement in ADR reporting. Further, larger scale studies with the involvement of more countries are needed to better understand the trends in ADR reporting, and multifaceted interventions are warranted to be installed to enhance ADR reporting.</p></section><section id="sec5"><h3 class="pmc_sec_title">Supplementary Information</h3>
<p>The online version contains supplementary material available at 10.1007/s00228-025-03862-2.</p></section><section id="kwd-group1" lang="en" class="kwd-group"><p><strong>Keywords:</strong> Adverse drug reactions, Consumers, Health care professionals, Anatomical Therapeutic Chemical classification system, Joinpoint regression analysis</p></section></section><section id="Sec1"><h2 class="pmc_sec_title">Introduction</h2>
<p id="Par5">Across the world, adverse drug reactions (ADRs) remain a huge burden to health care, leading to significant morbidity, mortality [<a href="#CR1" class="usa-link" aria-describedby="CR1">1</a>], and costs [<a href="#CR2" class="usa-link" aria-describedby="CR2">2</a>]. The World Health Organization (WHO) defines an ADR as “a response which is noxious and unintended, and which occurs at doses normally used in humans for the prophylaxis, diagnosis, or therapy of disease, or for the modification of physiological function” [<a href="#CR3" class="usa-link" aria-describedby="CR3">3</a>]. The data show that approximately 5% of all the hospitalizations are due to ADRs [<a href="#CR4" class="usa-link" aria-describedby="CR4">4</a>], and the incidence of fatal ADRs ranges from 0.2% to 0.5% [<a href="#CR5" class="usa-link" aria-describedby="CR5">5</a>–<a href="#CR7" class="usa-link" aria-describedby="CR7">7</a>]. ADRs are considered one of the top 10 causes of all deaths in the developed world [<a href="#CR8" class="usa-link" aria-describedby="CR8">8</a>]. A meta-analysis by Lazarou et al. in 1998 concluded that ADRs might rank from the fourth to sixth leading cause of death in the USA [<a href="#CR5" class="usa-link" aria-describedby="CR5">5</a>]. It is estimated that the annual costs of ADRs are more than $13 billion in Canada [<a href="#CR9" class="usa-link" aria-describedby="CR9">9</a>], $30 billion in the USA [<a href="#CR10" class="usa-link" aria-describedby="CR10">10</a>], $460 million in Australia [<a href="#CR11" class="usa-link" aria-describedby="CR11">11</a>], and £2.2 billion in the UK [<a href="#CR12" class="usa-link" aria-describedby="CR12">12</a>].</p>
<p id="Par6">Traditionally, health care professionals (HCPs) have been considered a key source of spontaneous ADR reporting [<a href="#CR13" class="usa-link" aria-describedby="CR13">13</a>]. However, underreporting is a well-recognized issue not only among HCPs [<a href="#CR14" class="usa-link" aria-describedby="CR14">14</a>, <a href="#CR15" class="usa-link" aria-describedby="CR15">15</a>] but also among patients [<a href="#CR17" class="usa-link" aria-describedby="CR17">17</a>, <a href="#CR18" class="usa-link" aria-describedby="CR18">18</a>]. Organizations such as the WHO and the European Union (EU) have acknowledged the potential and value of patient reporting and have laid a sound foundation for major reforms in the EU pharmacovigilance system that took place in 2012 in the EU countries, including Lithuania. The introduction of the legal basis for the patient to report ADRs to national competent authorities was one of these major changes [<a href="#CR16" class="usa-link" aria-describedby="CR16">16</a>]. The new EU pharmacovigilance legislation mandated EU countries to encourage patient reporting directly to national competent authorities through awareness-raising activities and strengthening patients’ knowledge about pharmacovigilance, as well as to enable ADR reporting through easy and effective reporting mechanisms such as direct online reporting [<a href="#CR17" class="usa-link" aria-describedby="CR17">17</a>]. Furthermore, the new reporting rules enabled the provision of instructions on ADR reporting in drug package leaflets and labelling medicines that are being monitored particularly closely with a black inverted triangle to address the need for enhanced reporting [<a href="#CR19" class="usa-link" aria-describedby="CR19">19</a>, <a href="#CR20" class="usa-link" aria-describedby="CR20">20</a>]. Even after 18 months of this legislation being operational, positive results in patient safety and an overall increase in ADR reports by consumers were observed [<a href="#CR19" class="usa-link" aria-describedby="CR19">19</a>].</p>
<p id="Par7">Since then, many studies have clearly shown considerable patients’ contributions to spontaneous ADR reporting [<a href="#CR16" class="usa-link" aria-describedby="CR16">16</a>, <a href="#CR20" class="usa-link" aria-describedby="CR20">20</a>–<a href="#CR22" class="usa-link" aria-describedby="CR22">22</a>]. However, to the best of our knowledge, no study investigating the trends in reporting ADRs by consumers and HCPs within the period after 2012 has been carried out to date. Therefore, the aim of this study was to determine trends in overall ADR reporting, the ratio of HCP-to-consumer ADR reporting, and the ratio of serious-to-nonserious ADR reporting for an 11-year period in the selected non-EU and EU countries that had implemented systems for consumers’ reporting before the 2012 EU pharmacovigilance legislation and those that did not have. Moreover, we aimed to identify the most frequently reported medications causing ADRs.</p></section><section id="Sec2"><h2 class="pmc_sec_title">Materials and methods</h2>
<section id="Sec3"><h3 class="pmc_sec_title">Study design</h3>
<p id="Par8">This study was carried out from February 2023 to March 2024. A questionnaire along with the study purpose was sent to the national competent authorities of the selected countries via e-mail. The selected countries (<em>n</em> = 15) included several non-EU countries and the member states of the EU that had established systems for ADR reporting by patients before 2012 (Australia, Canada, the USA, the UK (now former EU country), the Netherlands, Denmark, France, Italy, and Sweden) as well as some EU countries where patient reporting became available after the adoption of the new EU pharmacovigilance legislation (Portugal, Finland, Belgium, Estonia, Latvia, and Lithuania). The contact information was taken from the official websites of the national competent authorities. If the response was not received, the questionnaire was resent repeatedly within the period of 4–8 weeks. Of the 15 countries selected, the national competent authorities of 8 countries, namely Belgium, Canada, Finland, Lithuania, the Netherlands, Portugal, Sweden, and the UK, answered and provided the information requested. For Canada, the data related to COVID-19 vaccination were additionally collected from the Canadian Adverse Events Following Immunization Surveillance System webpage [<a href="#CR23" class="usa-link" aria-describedby="CR23">23</a>]. The 4-item questionnaire asked to provide the following data by year for the period from 2012 until 2022: the total number of ADR reports, the numbers of ADRs reported separately by HCPs and consumers, the numbers of serious and non-serious ADRs, and top 5 medication groups causing ADRs by the Anatomical Therapeutic Chemical (ATC) classification system [<a href="#CR24" class="usa-link" aria-describedby="CR24">24</a>]. This system classifies active substances in a hierarchical manner with five different levels. There are 14 main anatomical/pharmacological groups that are further divided into the 2nd level (pharmacological or therapeutic subgroup), 3rd and 4 th levels (chemical, pharmacological, or therapeutic subgroup), and 5 th level (chemical substance) [<a href="#CR24" class="usa-link" aria-describedby="CR24">24</a>]. We analyzed top 5 medication groups causing ADRs by the 2nd level (therapeutic subgroup).</p>
<p id="Par9">HCPs were considered individuals licensed, registered, or certified under the laws or regulations of a particular country to provide health care services (physicians, pharmacists, and nurses). Consumers were defined as individuals that were not HCPs (patients or their relatives). A serious ADR was defined as an adverse reaction that results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, or causes a congenital abnormality/birth defect [<a href="#CR25" class="usa-link" aria-describedby="CR25">25</a>].</p></section><section id="Sec4"><h3 class="pmc_sec_title">Data analysis</h3>
<p id="Par10">The overall numbers of ADRs were converted to incidence rates per 100,000 population using the data on the total population obtained from the national statistics authorities of each selected country. The ratios of HCP-to-consumer ADR reporting and the ratios of serious-to-nonserious ADR reporting were calculated for each country by year.</p>
<p id="Par11">The Joinpoint Regression Program version 5.0 (Division of Cancer Control and Population Sciences, National Cancer Institute, Information Management Services, Inc., Calverton, MD) was used to perform the analysis of trends. We used ADR reporting rates, the ratio of HCP-to-consumer ADR reporting, and the ratio of serious-to-nonserious ADR reporting as inputs. The join point regression models employ joined linear segments on a logarithmic scale to define the year(s) when significant changes in trends occurred, i.e., identifies the periods that can be separated by inflection points, so-called joinpoints, and determines the pattern of a trend (upward, downward, or stationery). The number of joinpoints is obtained using permutation tests via Monte Carlo resampling. For the number of data points between 7 and 11, only one join point is available (in our study, we analyzed data for the 11-year period). Which model is better—with one or no joinpoint—is determined based on the Weighted Bayesian Information Criterion (WBIC). The model with a smaller WBIC is better.</p>
<p id="Par12">Once the line segments have been established, the estimated annual percent change (APC) is used to describe the magnitude and direction of trends in the ADR reporting rate, ratio of HCP-to-consumer ADR reporting, or ratio of serious-to-nonserious ADR reporting. Testing the hypothesis (two-sided <em>p</em> value = 0.05) that the APC is equal to zero is equivalent to testing the hypothesis that the trend is neither increasing nor decreasing. To compare trends over the whole period, the average annual percent change (AAPC) is estimated. When there are no joinpoints, the APC is constant and equals the AAPC. The 95% confidence intervals (95% CI) for APC and AAPC were calculated using the parametric method. The APC or the AAPC is statistically significant when its 95% CI does not include zero.</p>
<p id="Par13">For the evaluation of the most common medications causing ADRs over the study period in each country, we determined the top 5 most frequently reported medication groups classified according to the ATC classification system (ATC second level). The data on the therapeutic groups according to the ATC system were ranked as follows: the first place, the second place, and so on. The rank information was converted into a numerical format based on a 5-point scale: the first place got 5 points, while the fifth place got 1 point. If any therapeutic subgroup did not appear in the top 5 in a particular year, no points were given. The points over the whole period were added up to obtain a total score based on which the top 5 most frequently reported therapeutic subgroups were identified for each country. Later, we determined the top 10 most frequently reported therapeutic subgroups by the total score across all countries. The stability of ranks over the years for each country was tested by Friedman’s test; differences in the distributions of ranks were not significant if <em>p</em> &gt; 0.05.</p>
<p id="Par14">Data analysis was carried out using MS Excel and SPSS version 29 programs.</p></section></section><section id="Sec5"><h2 class="pmc_sec_title">Results</h2>
<section id="Sec6"><h3 class="pmc_sec_title">Overall trends in ADR reporting in eight countries, 2012–2022</h3>
<p id="Par15">Trends in ADR reporting in eight selected countries during the study period of 2012–2022 are shown in Table <a href="#Tab1" class="usa-link">1</a> and Fig. <a href="#Fig1" class="usa-link">1</a> (incidence rates per 100,000 population for each country are shown in Supplementary Table <a href="#MOESM1" class="usa-link">1</a>). The analysis revealed that ADR reporting rates during the 11-year period increased significantly in all the countries except for Belgium. The greatest AAPC was observed for Lithuania (32.34; 95% CI, 16.8 to 50.0), followed by the Netherlands (24.2; 95% CI, 6.8 to 44.5) and the UK (22.9; 95% CI, 5.6 to 43.0), while the lowest was in Canada (10.3; 95% CI, 7.4 to 13.3).
</p>
<section class="tw xbox font-sm" id="Tab1"><h4 class="obj_head">Table 1.</h4>
<div class="caption p"><p>Trends in adverse drug reaction reporting in eight countries, 2012–2022</p></div>
<div class="tbl-box p" tabindex="0"><table class="content" frame="hsides" rules="groups">
<thead><tr>
<th align="left" colspan="1" rowspan="1">Country</th>
<th align="left" colspan="1" rowspan="1">Period</th>
<th align="left" colspan="1" rowspan="1">APC (95% CI)</th>
<th align="left" colspan="1" rowspan="1">AAPC (95% CI)</th>
</tr></thead>
<tbody>
<tr><td align="left" colspan="4" rowspan="1">Non-EU and EU countries having consumer reporting systems before 2012</td></tr>
<tr>
<td align="left" colspan="1" rowspan="1">  Canada</td>
<td align="center" colspan="1" rowspan="1">2012–2022</td>
<td align="left" colspan="1" rowspan="1">10.3* (7.4; 13.3)</td>
<td align="left" colspan="1" rowspan="1">10.3* (7.4; 13.3)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">  UK</td>
<td align="center" colspan="1" rowspan="1">2012–2022</td>
<td align="left" colspan="1" rowspan="1">22.9* (5.6; 43.0)</td>
<td align="left" colspan="1" rowspan="1">22.9* (5.6; 43.0)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">  Netherlands</td>
<td align="center" colspan="1" rowspan="1">2012–2022</td>
<td align="left" colspan="1" rowspan="1">24.2* (6.8; 44.5)</td>
<td align="left" colspan="1" rowspan="1">24.2* (6.8; 44.5)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">  Sweden</td>
<td align="center" colspan="1" rowspan="1">2012–2022</td>
<td align="left" colspan="1" rowspan="1">15.7* (0.9; 32.6)</td>
<td align="left" colspan="1" rowspan="1">15.7* (0.9; 32.6)</td>
</tr>
<tr><td align="left" colspan="4" rowspan="1">EU countries that implemented consumer ADR reporting systems after 2012</td></tr>
<tr>
<td align="left" rowspan="2" colspan="1">  Belgium</td>
<td align="center" colspan="1" rowspan="1">2012–2019</td>
<td align="left" colspan="1" rowspan="1">6.5 (− 29.7; 61.3)</td>
<td align="left" rowspan="2" colspan="1">39.8 (− 10.0; 117.1)</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1">2019–2022</td>
<td align="left" colspan="1" rowspan="1">164.0 (− 44.2; 1149.7)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">  Finland</td>
<td align="center" colspan="1" rowspan="1">2012–2022</td>
<td align="left" colspan="1" rowspan="1">15.4* (1.8; 31.0)</td>
<td align="left" colspan="1" rowspan="1">15.4* (1.8; 31.0)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">  Lithuania</td>
<td align="center" colspan="1" rowspan="1">2012–2022</td>
<td align="left" colspan="1" rowspan="1">32.34* (16.8; 50.0)</td>
<td align="left" colspan="1" rowspan="1">32.34* (16.8; 50.0)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">  Portugal</td>
<td align="center" colspan="1" rowspan="1">2012–2022</td>
<td align="left" colspan="1" rowspan="1">18.0* (7.3; 29.9)</td>
<td align="left" colspan="1" rowspan="1">18.0* (7.3; 29.9)</td>
</tr>
</tbody>
</table></div>
<div class="p text-right font-secondary"><a href="table/Tab1/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<div class="tw-foot p"><div class="fn" id="_fn_p18">
<p><em>APC</em> annual percent change, <em>AAPC</em> average annual percent change</p>
<p> *Indicates that the APC or the AAPC is significantly different from zero (<em>p</em> &lt; 0.05)</p>
</div></div></section><figure class="fig xbox font-sm" id="Fig1"><h4 class="obj_head">Fig. 1.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=12398448_228_2025_3862_Fig1_HTML.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5bed/12398448/59a483639fd6/228_2025_3862_Fig1_HTML.jpg" loading="lazy" id="MO1" height="441" width="737" alt="Fig. 1"></a></p>
<div class="p text-right font-secondary"><a href="figure/Fig1/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Trends in adverse drug reaction reporting in eight countries, 2012–2022. The dots represent the values for a particular year. Trends are depicted with a regression line. To better visualize a separate trend for each country, the extreme values (related to the years of the COVID-19 pandemic) are not shown by shortening the scale on the <em>y</em> axis. *Indicates that the APC is significantly different from zero (<em>p</em> &lt; 0.05)</p></figcaption></figure><p id="Par16">One joinpoint was identified only in Belgium in 2019. However, in Belgium, an upward trend for both periods was insignificant (APC<sub>2012–2019</sub> = 6.5; 95% CI, − 29.7 to 61.3) and APC<sub>2019–2022</sub> = 164.0; 95% CI, − 44.2 to 1149.7). In other countries, the joinpoint regression analysis showed no join point; therefore, the APC is the same as the AAPC.</p></section><section id="Sec7"><h3 class="pmc_sec_title">Changes in the ratio of ADRs reported by HCPs and consumers, 2012–2022</h3>
<p id="Par17">During the study period, the ratios of HCP-to-consumer ADR reporting were significantly decreasing in all the countries (AAPC range, − 43.7 to − 24.9) except for Canada where an opposite significant trend toward an increasing HCP reporting rate (AAPC of 3.9; 95% CI, 0.5 to 7.4) was observed for 2012–2020 (Table <a href="#Tab2" class="usa-link">2</a>, Fig. <a href="#Fig2" class="usa-link">2</a>, and Supplementary Table <a href="#MOESM1" class="usa-link">2</a>). The greatest negative AAPC was documented for Lithuania (− 43.7; 95% CI, − 60.4 to − 19.9) followed by Finland (− 34.1; 95% CI, − 43.7 to − 22.9) and Belgium (− 32.4; 95% CI, − 38.3 to − 25.9).
</p>
<section class="tw xbox font-sm" id="Tab2"><h4 class="obj_head">Table 2.</h4>
<div class="caption p"><p>Trends in the ratio of adverse drug reactions reported by health care professionals and consumers in eight countries, 2012–2022<sup>a</sup></p></div>
<div class="tbl-box p" tabindex="0"><table class="content" frame="hsides" rules="groups">
<thead><tr>
<th align="left" colspan="1" rowspan="1">Country</th>
<th align="left" colspan="1" rowspan="1">Period</th>
<th align="left" colspan="1" rowspan="1">APC (95% CI)</th>
<th align="left" colspan="1" rowspan="1">AAPC (95% CI)</th>
</tr></thead>
<tbody>
<tr><td align="left" colspan="4" rowspan="1">Non-EU and EU countries having consumer reporting systems before 2012</td></tr>
<tr>
<td align="left" colspan="1" rowspan="1">  Canada<sup>a</sup>
</td>
<td align="center" colspan="1" rowspan="1">2012–2020</td>
<td align="left" colspan="1" rowspan="1">3.9* (0.5; 7.4)</td>
<td align="left" colspan="1" rowspan="1">3.9* (0.5; 7.4)</td>
</tr>
<tr>
<td align="left" rowspan="2" colspan="1">  UK</td>
<td align="center" colspan="1" rowspan="1">2012–2019</td>
<td align="left" colspan="1" rowspan="1"> − 11.1 (− 30.2; 13.3)</td>
<td align="left" rowspan="2" colspan="1"> − 24.9* (− 41.8; − 2.9)</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1">2019–2022</td>
<td align="left" colspan="1" rowspan="1"> − 49.3 (− 79.5; 25.3)</td>
</tr>
<tr>
<td align="left" rowspan="2" colspan="1">  Netherlands</td>
<td align="center" colspan="1" rowspan="1">2012–2020</td>
<td align="left" colspan="1" rowspan="1"> − 15.7* (− 19.7; − 11.4)</td>
<td align="left" rowspan="2" colspan="1"> − 31.3* (− 36.2; − 25.6)</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1">2020–2022</td>
<td align="left" colspan="1" rowspan="1"> − 69.7* (− 80.7; − 52.3)</td>
</tr>
<tr>
<td align="left" rowspan="2" colspan="1">  Sweden</td>
<td align="center" colspan="1" rowspan="1">2012–2019</td>
<td align="left" colspan="1" rowspan="1"> − 8.2 (− 20.9; 6.6)</td>
<td align="left" rowspan="2" colspan="1"> − 25.3* (− 36.2; − 12.5)</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1">2019–2022</td>
<td align="left" colspan="1" rowspan="1"> − 53.8* (− 73.5; − 19.3)</td>
</tr>
<tr><td align="left" colspan="4" rowspan="1">EU countries that implemented consumer ADR reporting systems after 2012</td></tr>
<tr>
<td align="left" colspan="1" rowspan="1">  Belgium</td>
<td align="center" colspan="1" rowspan="1">2012–2022</td>
<td align="left" colspan="1" rowspan="1"> − 32.4* (− 38.3; − 25.9)</td>
<td align="left" colspan="1" rowspan="1"> − 32.4* (− 38.3; − 25.9)</td>
</tr>
<tr>
<td align="left" rowspan="2" colspan="1">  Finland</td>
<td align="center" colspan="1" rowspan="1">2012–2020</td>
<td align="left" colspan="1" rowspan="1"> − 19.6* (− 27.1; − 11.4)</td>
<td align="left" rowspan="2" colspan="1"> − 34.1* (− 43.7; − 22.9)</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1">2020–2022</td>
<td align="left" colspan="1" rowspan="1"> − 70.2* (− 87.9; − 26.9)</td>
</tr>
<tr>
<td align="left" rowspan="2" colspan="1">  Lithuania</td>
<td align="center" colspan="1" rowspan="1">2012–2014</td>
<td align="left" colspan="1" rowspan="1"> − 82.4 (− 97.7; 32.9)</td>
<td align="left" rowspan="2" colspan="1"> − 43.7* (− 60.4; − 19.9)</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1">2014–2022</td>
<td align="left" colspan="1" rowspan="1"> − 24.7* (− 39.6; − 6.2)</td>
</tr>
<tr>
<td align="left" rowspan="2" colspan="1">  Portugal</td>
<td align="center" colspan="1" rowspan="1">2012–2014</td>
<td align="left" colspan="1" rowspan="1"> − 61.2 (− 88.5; 30.8)</td>
<td align="left" rowspan="2" colspan="1"> − 27.2* (− 41.1; − 10.0)</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1">2014–2022</td>
<td align="left" colspan="1" rowspan="1"> − 14.8* (− 25.4; − 2.8)</td>
</tr>
</tbody>
</table></div>
<div class="p text-right font-secondary"><a href="table/Tab2/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<div class="tw-foot p"><div class="fn" id="_fn_p24">
<p><em>APC</em> annual percent change, <em>AAPC</em> average annual percent change</p>
<p>*Indicates that the APC or the AAPC is significantly different from zero (<em>p</em> &lt; 0.05)</p>
<p><sup>a</sup>The trend for Canada was calculated for the period of 2012–2020 due to missing data for 2021 and 2022</p>
</div></div></section><figure class="fig xbox font-sm" id="Fig2"><h4 class="obj_head">Fig. 2.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=12398448_228_2025_3862_Fig2_HTML.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5bed/12398448/3e2be82cb4df/228_2025_3862_Fig2_HTML.jpg" loading="lazy" id="MO2" height="458" width="766" alt="Fig. 2"></a></p>
<div class="p text-right font-secondary"><a href="figure/Fig2/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Trends in the ratio of adverse drug reactions reported by health care professionals and consumers in eight countries, 2012–2022<sup>a</sup>. The dots represent the values for a particular year. Trends are depicted with a regression line. To better visualize a separate trend for each country, the extreme values (related to the years of the COVID-19 pandemic) are not shown by shortening the scale on the y axis. *Indicates that the APC is significantly different from zero (<em>p</em> &lt; 0.05). <sup>a</sup>The trend for Canada was calculated for the period of 2012–2020 due to missing data for 2021 and 2022</p></figcaption></figure><p id="Par18">The analysis found no joinpoints for Belgium and Canada, indicating stationary trends in the ratios of HCP-to-consumer ADR reporting over the study period in these countries. Regarding changes in trends in the one-joinpoint countries, joinpoints toward an accelerated decrease in the ratios, indicating increased reporting rates by consumers, were observed for Finland in 2020, Sweden in 2019, and the Netherlands in 2020. For Lithuania and Portugal, a joinpoint toward an accelerated increase in the ratios was recorded in 2014 for both countries, but it is worth noting that the APCs for the period of 2012–2014 were not statistically significant for both countries as well.</p></section><section id="Sec8"><h3 class="pmc_sec_title">Changes in the ratio of serious-to-nonserious ADR reporting, 2012–2022</h3>
<p id="Par19">During the study period, the ratios of serious-to-nonserious ADR reporting were significantly decreasing in more than half of the countries, namely Canada, Finland, Lithuania, the Netherlands, and Portugal (Table <a href="#Tab3" class="usa-link">3</a>, Fig. <a href="#Fig3" class="usa-link">3</a>, and Supplementary Table <a href="#MOESM1" class="usa-link">3</a>). The greatest negative AAPC was documented for Lithuania (− 32.9; 95% CI, − 38.4 to − 26.9), and the smallest for Canada (− 6.8; 95% CI, − 9.9 to − 3.7). Despite the AAPC for Belgium not being significant, analysis found a joinpoint in 2019 showing a significant downward trend for 2012–2019 (APC =  − 11.8; 95% CI, − 17.4 to − 5.7) and a significant upward trend for 2019–2022 (APC = 22.9; 95% CI, 8.6 to 39.2). Neither the APCs nor the AAPC were found to be significant for Sweden and the UK.
</p>
<section class="tw xbox font-sm" id="Tab3"><h4 class="obj_head">Table 3.</h4>
<div class="caption p"><p>Trends in the ratio of serious-to-nonserious adverse drug reaction reporting in eight countries, 2012–2022</p></div>
<div class="tbl-box p" tabindex="0"><table class="content" frame="hsides" rules="groups">
<thead><tr>
<th align="left" colspan="1" rowspan="1">Country</th>
<th align="left" colspan="1" rowspan="1">Period</th>
<th align="left" colspan="1" rowspan="1">APC (95% CI)</th>
<th align="left" colspan="1" rowspan="1">AAPC (95% CI)</th>
</tr></thead>
<tbody>
<tr><td align="left" colspan="4" rowspan="1">Non-EU and EU countries having consumer reporting systems before 2012</td></tr>
<tr>
<td align="left" colspan="1" rowspan="1">  Canada</td>
<td align="center" colspan="1" rowspan="1">2012–2022</td>
<td align="left" colspan="1" rowspan="1"> − 6.8* (− 9.9; − 3.7)</td>
<td align="left" colspan="1" rowspan="1"> − 6.8* (− 9.9; − 3.7)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">  UK</td>
<td align="center" colspan="1" rowspan="1">2012–2022</td>
<td align="left" colspan="1" rowspan="1"> − 3.4 (− 10.9; 20.0)</td>
<td align="left" colspan="1" rowspan="1"> − 3.4 (− 10.9; 20.0)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">  Netherlands</td>
<td align="center" colspan="1" rowspan="1">2012–2022</td>
<td align="left" colspan="1" rowspan="1"> − 16.4* (− 22.2; − 10.2)</td>
<td align="left" colspan="1" rowspan="1"> − 16.4* (− 22.2; − 10.2)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">  Sweden</td>
<td align="center" colspan="1" rowspan="1">2012–2022</td>
<td align="left" colspan="1" rowspan="1"> − 10.2 (− 19.4; 0.1)</td>
<td align="left" colspan="1" rowspan="1"> − 10.2 (− 19.4; 0.1)</td>
</tr>
<tr><td align="left" colspan="4" rowspan="1">EU countries that implemented consumer ADR reporting systems after 2012</td></tr>
<tr>
<td align="left" rowspan="2" colspan="1">  Belgium</td>
<td align="center" colspan="1" rowspan="1">2012–2019</td>
<td align="left" colspan="1" rowspan="1"> − 11.8* (− 17.4; − 5.7)</td>
<td align="left" rowspan="2" colspan="1">0.7 (− 4.3; 6.0)</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1">2019–2022</td>
<td align="left" colspan="1" rowspan="1">22.9* (8.6; 39.2)</td>
</tr>
<tr>
<td align="left" rowspan="2" colspan="1">  Finland</td>
<td align="center" colspan="1" rowspan="1">2012–2019</td>
<td align="left" colspan="1" rowspan="1"> − 26.4* (− 35.8; − 15.7)</td>
<td align="left" rowspan="2" colspan="1"> − 18.5* (− 29.4; − 5.9)</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1">2019–2022</td>
<td align="left" colspan="1" rowspan="1">3.5 (− 37.7; 72.0)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">  Lithuania</td>
<td align="center" colspan="1" rowspan="1">2012–2022</td>
<td align="left" colspan="1" rowspan="1"> − 32.9* (− 38.4; − 26.9)</td>
<td align="left" colspan="1" rowspan="1"> − 32.9* (− 38.4; − 26.9)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">  Portugal</td>
<td align="center" colspan="1" rowspan="1">2012–2022</td>
<td align="left" colspan="1" rowspan="1"> − 16.7* (− 26.1; − 6.2)</td>
<td align="left" colspan="1" rowspan="1"> − 16.7* (− 26.1; − 6.2)</td>
</tr>
</tbody>
</table></div>
<div class="p text-right font-secondary"><a href="table/Tab3/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<div class="tw-foot p"><div class="fn" id="_fn_p31">
<p><em>APC</em> annual percent change, <em>AAPC</em> average annual percent change</p>
<p>*Indicates that the APC or the AAPC is significantly different from zero (<em>p</em> &lt; 0.05)</p>
</div></div></section><figure class="fig xbox font-sm" id="Fig3"><h4 class="obj_head">Fig. 3.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=12398448_228_2025_3862_Fig3_HTML.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5bed/12398448/5c897b5db1ba/228_2025_3862_Fig3_HTML.jpg" loading="lazy" id="MO3" height="393" width="656" alt="Fig. 3"></a></p>
<div class="p text-right font-secondary"><a href="figure/Fig3/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Trends in the ratio of serious-to-nonserious adverse drug reaction reporting in eight countries, 2012–2022. The dots represent the values for a particular year. Trends are depicted with a regression line. To better visualize a separate trend for each country, the extreme values (related to the years of the COVID-19 pandemic) are not shown by shortening the scale on the <em>y</em> axis. *Indicates that the APC is significantly different from zero (<em>p</em> &lt; 0.05)</p></figcaption></figure></section><section id="Sec9"><h3 class="pmc_sec_title">The most frequently reported drugs causing adverse drug reactions</h3>
<p id="Par20">In this part of our study, we evaluated data from seven countries. Table <a href="#Tab4" class="usa-link">4</a> shows the top 5 most frequently reported drug groups classified according to the ATC classification system. Unfortunately, we could not include the data from Belgium as no information on this was provided.
</p>
<section class="tw xbox font-sm" id="Tab4"><h4 class="obj_head">Table 4.</h4>
<div class="caption p"><p>The top 5 most frequently reported therapeutic subgroups (ATC second level) by the total score in seven selected countries (excluding Belgium)</p></div>
<div class="tbl-box p" tabindex="0"><table class="content" frame="hsides" rules="groups">
<thead><tr>
<th align="left" colspan="1" rowspan="1">Country</th>
<th align="left" colspan="1" rowspan="1">TOP rank</th>
<th align="left" colspan="1" rowspan="1">ATC therapeutic subgroup</th>
<th align="left" colspan="1" rowspan="1">Total score<sup>a</sup>
</th>
</tr></thead>
<tbody>
<tr>
<td align="left" rowspan="5" colspan="1">Canada</td>
<td align="left" colspan="1" rowspan="1">1</td>
<td align="left" colspan="1" rowspan="1">Immunosuppressants (L04)</td>
<td align="left" colspan="1" rowspan="1">54</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">2</td>
<td align="left" colspan="1" rowspan="1">Antineoplastic agents (L01)</td>
<td align="left" colspan="1" rowspan="1">42</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">3</td>
<td align="left" colspan="1" rowspan="1">Psycholeptics (N05)</td>
<td align="left" colspan="1" rowspan="1">16</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">4</td>
<td align="left" colspan="1" rowspan="1">Analgesics (N02)</td>
<td align="left" colspan="1" rowspan="1">15</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">5</td>
<td align="left" colspan="1" rowspan="1">Drugs for obstructive airway diseases (R03)</td>
<td align="left" colspan="1" rowspan="1">15</td>
</tr>
<tr>
<td align="left" rowspan="5" colspan="1">Finland</td>
<td align="left" colspan="1" rowspan="1">1</td>
<td align="left" colspan="1" rowspan="1">Vaccines (J07)</td>
<td align="left" colspan="1" rowspan="1">54</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">2</td>
<td align="left" colspan="1" rowspan="1">Other gynecologicals (G02)</td>
<td align="left" colspan="1" rowspan="1">29</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">3</td>
<td align="left" colspan="1" rowspan="1">Psycholeptics (N05)</td>
<td align="left" colspan="1" rowspan="1">21</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">4</td>
<td align="left" colspan="1" rowspan="1">Antithrombotic agents (B01)</td>
<td align="left" colspan="1" rowspan="1">20</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">5</td>
<td align="left" colspan="1" rowspan="1">Immunosuppressants (L04)</td>
<td align="left" colspan="1" rowspan="1">12</td>
</tr>
<tr>
<td align="left" rowspan="5" colspan="1">Lithuania<sup>b</sup>
</td>
<td align="left" colspan="1" rowspan="1">1</td>
<td align="left" colspan="1" rowspan="1">Antineoplastic agents (L01)</td>
<td align="left" colspan="1" rowspan="1">35</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">2</td>
<td align="left" colspan="1" rowspan="1">Vaccines (J07)</td>
<td align="left" colspan="1" rowspan="1">34</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">3</td>
<td align="left" colspan="1" rowspan="1">Psycholeptics (N05)</td>
<td align="left" colspan="1" rowspan="1">16</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">4</td>
<td align="left" colspan="1" rowspan="1">Antithrombotic agents (B01)</td>
<td align="left" colspan="1" rowspan="1">8</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">5</td>
<td align="left" colspan="1" rowspan="1">Immunosuppressants (L04)</td>
<td align="left" colspan="1" rowspan="1">7</td>
</tr>
<tr>
<td align="left" rowspan="5" colspan="1">Netherlands</td>
<td align="left" colspan="1" rowspan="1">1</td>
<td align="left" colspan="1" rowspan="1">Vaccines (J07)</td>
<td align="left" colspan="1" rowspan="1">54</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">2</td>
<td align="left" colspan="1" rowspan="1">Antibacterials for systemic use (J01)</td>
<td align="left" colspan="1" rowspan="1">35</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">3</td>
<td align="left" colspan="1" rowspan="1">Psychoanaleptics (N06)</td>
<td align="left" colspan="1" rowspan="1">30</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">4</td>
<td align="left" colspan="1" rowspan="1">Immunosuppressants (L04)</td>
<td align="left" colspan="1" rowspan="1">18</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">5</td>
<td align="left" colspan="1" rowspan="1">Antithrombotic agents (B01)</td>
<td align="left" colspan="1" rowspan="1">6</td>
</tr>
<tr>
<td align="left" rowspan="5" colspan="1">Portugal</td>
<td align="left" colspan="1" rowspan="1">1</td>
<td align="left" colspan="1" rowspan="1">Antineoplastic agents (L01)</td>
<td align="left" colspan="1" rowspan="1">48</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">2</td>
<td align="left" colspan="1" rowspan="1">Immunosuppressants (L04)</td>
<td align="left" colspan="1" rowspan="1">42</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">3</td>
<td align="left" colspan="1" rowspan="1">Antibacterials for systemic use (J01)</td>
<td align="left" colspan="1" rowspan="1">28</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">4</td>
<td align="left" colspan="1" rowspan="1">Vaccines (J07)</td>
<td align="left" colspan="1" rowspan="1">26</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">5</td>
<td align="left" colspan="1" rowspan="1">Antivirals for systemic use (J05)</td>
<td align="left" colspan="1" rowspan="1">17</td>
</tr>
<tr>
<td align="left" rowspan="5" colspan="1">Sweden</td>
<td align="left" colspan="1" rowspan="1">1</td>
<td align="left" colspan="1" rowspan="1">Vaccines (J07)</td>
<td align="left" colspan="1" rowspan="1">48</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">2</td>
<td align="left" colspan="1" rowspan="1">Antithrombotic agents (B01)</td>
<td align="left" colspan="1" rowspan="1">33</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">3</td>
<td align="left" colspan="1" rowspan="1">Other gynecologicals (G02)</td>
<td align="left" colspan="1" rowspan="1">21</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">4</td>
<td align="left" colspan="1" rowspan="1">Immunosuppressants (L04)</td>
<td align="left" colspan="1" rowspan="1">12</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">5</td>
<td align="left" colspan="1" rowspan="1">Psychoanaleptics (N06)</td>
<td align="left" colspan="1" rowspan="1">12</td>
</tr>
<tr>
<td align="left" rowspan="5" colspan="1">UK</td>
<td align="left" colspan="1" rowspan="1">1</td>
<td align="left" colspan="1" rowspan="1">Vaccines (J07)</td>
<td align="left" colspan="1" rowspan="1">51</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">2</td>
<td align="left" colspan="1" rowspan="1">Antibacterials for systemic use (J01)</td>
<td align="left" colspan="1" rowspan="1">45</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">3</td>
<td align="left" colspan="1" rowspan="1">Antithrombotic agents (B01)</td>
<td align="left" colspan="1" rowspan="1">26</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">4</td>
<td align="left" colspan="1" rowspan="1">Other nervous system drugs (N07)</td>
<td align="left" colspan="1" rowspan="1">11</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">5</td>
<td align="left" colspan="1" rowspan="1">Psychoanaleptics (N06)</td>
<td align="left" colspan="1" rowspan="1">11</td>
</tr>
</tbody>
</table></div>
<div class="p text-right font-secondary"><a href="table/Tab4/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<div class="tw-foot p"><div class="fn" id="_fn_p36">
<p><sup>a</sup>The top 5 most frequently reported therapeutic groups according to the ATC classification system (ATC second level) causing ADRs were ranked on a 5-point scale for every year by giving 5 points to the most frequently reported therapeutic group and 1 point to the least frequently reported therapeutic group. If a certain therapeutic group did not appear in the top 5 in a particular year, no points were given. The points over the whole period were added up to obtain a total score based on which the top 5 most frequently reported therapeutic groups were identified for each country</p>
<p><sup>b</sup>For Lithuania, the top 5 ATC rank is shown for the period of 2015–2022</p>
</div></div></section><p id="Par21">The top 5 most frequently reported ATC drug groups did not differ statistically significantly in every country over the study period. Vaccines (J07) were the most frequently reported ATC group in four countries, namely Finland, the Netherlands, Sweden and the UK. In Lithuanian, they ranked second, and in Portugal, fourth. Meanwhile, in Canada, they were not found to be present among the top 5 most common.</p>
<p id="Par22">Immunosuppressants (L04) were the most frequently reported ATC group in Canada; in Portugal, second; in Sweden and the Netherlands, fourth; and in Finland and Lithuania, fifth. Antineoplastic agents (L01) ranked first in Portugal and Lithuania and second in Canada. In the Netherlands, Finland, Sweden, and the UK, these drugs were not among the top 5 most frequently reported therapeutic groups.</p>
<p id="Par23">Psycholeptics (N05) ranked third in Canada, Finland, and Lithuania; in the Netherlands, Portugal, Sweden, and the UK, they were not among the top 5 most frequently reported therapeutic groups. Antithrombotic agents (B01) ranked second in Sweden; in the UK, third; in Finland and Lithuania, fourth; in the Netherlands, fifth; and in the remaining countries, they were not among the top 5 most frequently reported therapeutic groups.</p>
<p id="Par24">Antibacterials for systemic use (J01) ranked second in the Netherlands and the UK and third in Portugal. Other gynecologicals (G02) were among the top 5 most frequently reported therapeutic groups only in two countries: Finland (second place) and Sweden (third place).</p>
<p id="Par25">The top 10 most frequently reported therapeutic groups by the total score across all countries are displayed in Table <a href="#Tab5" class="usa-link">5</a>. Vaccines (J07) ranked first, followed by immunosuppressants (L04), antineoplastic agents (L01), antibacterials for systemic use (J01), and antithrombotic agents (B01).
</p>
<section class="tw xbox font-sm" id="Tab5"><h4 class="obj_head">Table 5.</h4>
<div class="caption p"><p>The top 10 most frequently reported therapeutic groups (ATC second level) causing adverse drug reactions by the total score across all countries (excluding Belgium)</p></div>
<div class="tbl-box p" tabindex="0"><table class="content" frame="hsides" rules="groups">
<thead><tr>
<th align="left" colspan="1" rowspan="1">ATC therapeutic subgroup</th>
<th align="left" colspan="1" rowspan="1">Total score<sup>a</sup>
</th>
<th align="left" colspan="1" rowspan="1">Top rank</th>
</tr></thead>
<tbody>
<tr>
<td align="left" colspan="1" rowspan="1">Vaccines (J07)</td>
<td align="left" colspan="1" rowspan="1">276</td>
<td align="left" colspan="1" rowspan="1">1</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Immunosuppressants (L04)</td>
<td align="left" colspan="1" rowspan="1">148</td>
<td align="left" colspan="1" rowspan="1">2</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Antineoplastic agents (L01)</td>
<td align="left" colspan="1" rowspan="1">136</td>
<td align="left" colspan="1" rowspan="1">3</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Antibacterials for systemic use (J01)</td>
<td align="left" colspan="1" rowspan="1">113</td>
<td align="left" colspan="1" rowspan="1">4</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Antithrombotic agents (B01)</td>
<td align="left" colspan="1" rowspan="1">94</td>
<td align="left" colspan="1" rowspan="1">5</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Psycholeptics (N05)</td>
<td align="left" colspan="1" rowspan="1">58</td>
<td align="left" colspan="1" rowspan="1">6</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Psychoanaleptics (N06)</td>
<td align="left" colspan="1" rowspan="1">56</td>
<td align="left" colspan="1" rowspan="1">7</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Other gynecologicals (G02)</td>
<td align="left" colspan="1" rowspan="1">50</td>
<td align="left" colspan="1" rowspan="1">8</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Analgesics (N02)</td>
<td align="left" colspan="1" rowspan="1">24</td>
<td align="left" colspan="1" rowspan="1">9</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Antivirals for systemic use (J05)</td>
<td align="left" colspan="1" rowspan="1">18</td>
<td align="left" colspan="1" rowspan="1">10</td>
</tr>
</tbody>
</table></div>
<div class="p text-right font-secondary"><a href="table/Tab5/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<div class="tw-foot p"><div class="fn" id="_fn_p44"><p><sup>a</sup>First, the top 5 most frequently reported therapeutic groups according to the ATC classification system (ATC second level) causing ADRs were determined as described in the footnotes of Table <a href="#Tab4" class="usa-link">4</a>. Later, the top 10 most frequently reported therapeutic groups by the total score across all countries were determined</p></div></div></section></section></section><section id="Sec10"><h2 class="pmc_sec_title">Discussion</h2>
<p id="Par26">Our study showed that the rates of overall ADR reporting during the 11-year period increased significantly in all the countries except for Belgium, with the greatest AAPC being in Lithuania and the lowest in Canada. While comparing the EU countries that implemented consumer ADR reporting systems after the 2012 EU pharmacovigilance legislation with those that had consumer reporting systems before 2012, we could not observe any obvious differences in tendencies between these two groups of countries. The ratios of HCP-to-consumer ADR reporting were significantly decreasing (indicating the increased rates of consumer reporting) in all the countries except for Canada, where an opposite significant trend toward an increasing HCP reporting rate was observed for 2012–2020. From the group of countries that implemented consumer ADR reporting systems after the 2012 EU legislation, three countries, namely Belgium, Finland, and Lithuania, had the greatest significant negative AAPC. The analysis of the ratios of serious-to-nonserious ADR reporting showed that Finland, Lithuania, and Portugal (countries that implemented consumer ADR reporting systems after the 2012 EU legislation) had the greatest negative AAPC; meanwhile, Canada had the smallest negative AAPC across all countries.</p>
<p id="Par27">ADRs are associated with higher mortality rates, greater rates of hospital admission, longer hospital stays, and increased health care expenditures. A systematic review done by Howard et al. in 2006 reported that drug-related admissions in the USA accounted for 4.2%–9.6% of all admissions; in Canada, 30.7%; in Australia, 5.7%–18.8%; and in Europe, 2.5%–12.5% [<a href="#CR26" class="usa-link" aria-describedby="CR26">26</a>]. Up to half of ADR-related admissions are regarded as preventable [<a href="#CR11" class="usa-link" aria-describedby="CR11">11</a>]. Given all these estimates, the underreporting rates of ADRs can be as high as 95% [<a href="#CR8" class="usa-link" aria-describedby="CR8">8</a>, <a href="#CR9" class="usa-link" aria-describedby="CR9">9</a>]. Despite Sweden being one of the leading countries in the world with ADR report numbers, the study by Bäckström et al. conducted at five hospitals in 2004 showed that the overall underreporting rate of serious ADRs was 86%, with an underreporting rate in one hospital being even 100% [<a href="#CR27" class="usa-link" aria-describedby="CR27">27</a>]. The causes of ADR underreporting by HCPs and consumers are complex [<a href="#CR18" class="usa-link" aria-describedby="CR18">18</a>, <a href="#CR28" class="usa-link" aria-describedby="CR28">28</a>], but most likely are associated with time restrictions for reporting, lack of knowledge of how and where to report, and difficulties in recognizing ADRs, as direct causality of an ADR appears to be difficult to determine [<a href="#CR8" class="usa-link" aria-describedby="CR8">8</a>]. Almost 50 years ago, British physician Inman was the first to indicate so-called seven deadly sins, namely ignorance, diffidence, indifference, ambition, complacency, guilt, and fear, as the reasons for ADR underreporting by HCPs [<a href="#CR29" class="usa-link" aria-describedby="CR29">29</a>]. Later, these reasons were updated and additionally included lethargy, insecurity, and unavailability of notification forms. An updated systematic review by García‑Abeijon in 2023 aimed at determining the factors associated with underreporting by HCPs by employing Inman’s “seven deadly sins” model [<a href="#CR28" class="usa-link" aria-describedby="CR28">28</a>]. This review indicated ignorance and lethargy as being the main determinants of underreporting (86% and 85%, respectively) followed by complacency (46%), diffidence (45%), and insecurity (34%). It concluded that very little had changed from 2009 despite all these factors being considered potentially modifiable with the help of educational interventions [<a href="#CR28" class="usa-link" aria-describedby="CR28">28</a>]. A survey carried out in Finland in 2022 reported that the main reason for non-reporting an ADR indicated by HCPs was that the ADR was already known, followed by the lack of time and knowledge of how to report [<a href="#CR30" class="usa-link" aria-describedby="CR30">30</a>]. Those HCPs who reported an ADR more than 5 times made up only 8%, while those who had not reported any ADRs during their careers accounted for even 42%. Seriousness and unexpectedness of an ADR were the main motivating factors to report [<a href="#CR30" class="usa-link" aria-describedby="CR30">30</a>]. The study by Li et al. investigating why hospital-based HCPs did not report ADRs found that knowing how to report ADRs, having been trained on ADR reporting, and encountering ADRs as part of clinical practice were significant predictors of reporting ADRs [<a href="#CR31" class="usa-link" aria-describedby="CR31">31</a>]. According to a recent study, there is a necessity to implement strategies to recognize, report, and monitor ADRs in hospital settings [<a href="#CR32" class="usa-link" aria-describedby="CR32">32</a>]. Nonspecific manifestations of ADRs often lead to difficulties for clinicians in recognizing ADRs and distinguishing them from underlying conditions [<a href="#CR33" class="usa-link" aria-describedby="CR33">33</a>]. The study by Gautron et al. concluded that providing HCPs with clear guidance on how to identify reportable suspected serious ADRs and to assess the likelihood of causality could improve medication safety [<a href="#CR34" class="usa-link" aria-describedby="CR34">34</a>]. Moreover, in some countries, patient reporting systems to encourage patients’ awareness to report an ADR have been promoted via HCPs, and activities to educate the public on the importance of reporting have been implemented [<a href="#CR35" class="usa-link" aria-describedby="CR35">35</a>].</p>
<p id="Par28">Contribution of all HCPs, including physicians, dentists, nurses, and pharmacists, is essential to improve drug safety. For many years, physicians have been considered the key source of ADR reporting as they serve as frontline health care providers acting directly at the patient’s bedside [<a href="#CR36" class="usa-link" aria-describedby="CR36">36</a>]. However, the role of other HCPs cannot be underestimated. Community and hospital pharmacists are highly perceived for their role in reporting ADRs in their daily practice as it is their core duties [<a href="#CR37" class="usa-link" aria-describedby="CR37">37</a>, <a href="#CR38" class="usa-link" aria-describedby="CR38">38</a>]. Moreover, nurses are in a unique position to monitor the patient’s responses to administered drugs and, consequently, to report potential ADRs if necessary [<a href="#CR39" class="usa-link" aria-describedby="CR39">39</a>, <a href="#CR40" class="usa-link" aria-describedby="CR40">40</a>]. Unfortunately, we could not perform an analysis showing the contribution of particular HCP groups to ADR reporting as not all countries we included in our study sent the separate numbers of ADRs for every HCP group. However, using the available data, we see that pharmacists’ input in ADR reporting differs across the countries. In Portugal, the percentage of ADR reports by pharmacists accounted for 40% to 50% during the 11-year period, while in Canada, the Netherlands, and Sweden, this percentage ranged between 10 and 15% of all ADR cases reported by HCPs. Only 1% to 2% of all ADRs were reported by pharmacists in Lithuania (data not shown). Regarding ADR reporting by nurses, we found that in Portugal, the percentage of ADR reports by nurses made up 10% to 27% of all ADR reports across the different years. In Sweden, this percentage was similar, varying from 9 to 17% (with one exception being 42% in 2021 year) despite in March of 2007, Sweden issued a legislative amendment that compelled nurses to report all ADRs to the national pharmacovigilance system [<a href="#CR40" class="usa-link" aria-describedby="CR40">40</a>].</p>
<p id="Par29">Under-reporting rates of ADRs could be reduced by direct patient reporting [<a href="#CR41" class="usa-link" aria-describedby="CR41">41</a>], and potential benefits of patient reporting have been documented in previous research. Blenkinsopp et al. summarized that patients might be more likely to identify a symptom as a suspected ADR than HCPs, might report different ADRs from those reported by HCPs, and might indicate new ADRs that had not been known [<a href="#CR42" class="usa-link" aria-describedby="CR42">42</a>]. Later, it was confirmed by Health Action International Europe that reports by patients were more direct as they came from persons who experienced the effects, provided more details, and were more explicit than those by HCPs [<a href="#CR43" class="usa-link" aria-describedby="CR43">43</a>]. Therefore, it is important to identify the factors that have an impact on voluntary patient reporting of ADRs to implement strategies for improving it [<a href="#CR44" class="usa-link" aria-describedby="CR44">44</a>]. Poor awareness, confusion about who should report the ADR, difficulties with reporting procedures, and lack of feedback on submitted reports have been identified as the main barriers to patient reporting of ADRs [<a href="#CR44" class="usa-link" aria-describedby="CR44">44</a>]. Other factors might play a role in consumers’ under-reporting of ADRs as well. The ADR online registration form differs across countries; different data are collected [<a href="#CR35" class="usa-link" aria-describedby="CR35">35</a>, <a href="#CR45" class="usa-link" aria-describedby="CR45">45</a>, <a href="#CR46" class="usa-link" aria-describedby="CR46">46</a>], and the number of clicks needed to reach an online report form varies from one to five [<a href="#CR35" class="usa-link" aria-describedby="CR35">35</a>]. It seems that countries with the most easily accessible ADR reporting forms online have the highest numbers of ADRs.</p>
<p id="Par30">The COVID-19 pandemic caused by SARS-CoV-2 represented an enormous challenge for health care systems. This unprecedented time of the pandemic prompted the rapid and successful development, authorization, and production of multiple vaccines within a year that resulted in massive vaccination campaigns [<a href="#CR47" class="usa-link" aria-describedby="CR47">47</a>, <a href="#CR48" class="usa-link" aria-describedby="CR48">48</a>]. More than 13 billion vaccine doses administered during the first 2 years of vaccination [<a href="#CR49" class="usa-link" aria-describedby="CR49">49</a>] affected the number of ADRs reported to pharmacovigilance systems across countries. As of June 2022, the reports linked to COVID-19 vaccines accounted for 14% (around 2 million reports) of all ADR reports submitted to EudraVigilance [<a href="#CR50" class="usa-link" aria-describedby="CR50">50</a>], reflecting the extent of the vaccination campaigns. Our analysis confirmed the upward trends in overall ADR reporting in 2021 and 2022, especially in 2021 where 1- to 39-fold greater incidences of ADR reporting per 100,000 population across the selected countries were documented. It is worth noting that Canada was the country with the smallest change in the overall incidence rate and lowest AAPC of 10.3 (95% CI, 7.4 to 13.3). Moreover, for Canada, a different trend as compared to other countries was observed in ADR reporting by HCPs and consumers: despite we were not able to get these data for Canada for the 2021 and 2022 years, the trend in the ratio of HCP-to-consumer ADR reporting for the period 2012–2020 was opposite (AAPC of 3.9; 95% CI, 0.5 to 7.4) as compared to other countries included in our study. It might be due to public awareness as Canada was the first country that started collecting consumers’ reports early on, likely around 1965, when the Canadian pharmacovigilance program was launched [<a href="#CR51" class="usa-link" aria-describedby="CR51">51</a>]. Among the countries included in our study, three EU countries had implemented patient reporting systems before 2012: Sweden since 1978 via KILEN, the Netherlands since 2003, and the UK since 2005 [<a href="#CR42" class="usa-link" aria-describedby="CR42">42</a>]. However, our study could not identify different trends in the ratio of HCP-to-consumer ADR reporting in these countries when compared with those EU countries that had no patient reporting systems implemented before 2012. Regarding serious-to-nonserious ADR reporting, Canada also stood out from other countries with significant changes: among the countries with significantly decreasing ratios of serious-to-nonserious ADR reporting, namely Finland, Lithuania, the Netherlands, and Portugal, the smallest negative AAPC being − 6.8 was obtained for Canada.</p>
<p id="Par31">During the study period, other pharmacovigilance-related initiatives that might have influenced HCP and consumer ADR reporting were launched. In Canada, the <em>Protecting Canadians from Unsafe Drugs Act</em> (Vanessa’s Law), enacted in 2014, introduced some amendments to Canada’s Food and Drugs Act. It included the requirements of mandatory reporting of serious ADRs and medical device events by health care institutions that came into effect in December 2019 [<a href="#CR52" class="usa-link" aria-describedby="CR52">52</a>]. However, this law mandates hospitals rather than HCPs to report serious ADRs, and from the very beginning, there were concerns that due to the subjectivity of HCPs to identify serious ADRs, health care institutions may face difficulties complying with this law [<a href="#CR34" class="usa-link" aria-describedby="CR34">34</a>]. Studies evaluating the impact of this law on the reporting of serious ADRs are scarce. The study by Djiokeng et al. aimed to determine if the enactment of Vanessa’s Law led to an increased reporting of serious ADRs that occurred after antiplatelet use in a tertiary academic hospital in Quebec. It appeared to have little effect on serious ADR reporting in this study [<a href="#CR53" class="usa-link" aria-describedby="CR53">53</a>]. In another study by Lavallée et al., a total of 500 electronic medical records of the same health care institution in Quebec from the period of January 1, 2018, to December 31, 2021, were reviewed [<a href="#CR54" class="usa-link" aria-describedby="CR54">54</a>]. The study found that no serious ADR had been reported to Health Canada even after the implementation of Vanessa’s Law. With the data of our study and their analysis, we cannot confirm or deny the impact of Vanessa’s Law on ADR reporting as we did not perform any cross-analysis by ADR seriousness and type of a reporter.</p>
<p id="Par32">It is worth mentioning that the Strengthening Collaboration for Operating Pharmacovigilance in Europe (SCOPE) Joint Action was initiated by a team of European regulators, which aimed at strengthening the pharmacovigilance network in Europe and improving operating pharmacovigilance capabilities and collaborative working [<a href="#CR55" class="usa-link" aria-describedby="CR55">55</a>]. This Joint Action in collaboration with national competent authorities and other organizations carried out additional activities such as social media awareness campaigns [<a href="#CR55" class="usa-link" aria-describedby="CR55">55</a>]. It has been reported that with the help of the 2017 campaign, a total of 2.3 million people were reached on social media and this led to an 11% increase in ADR reporting [<a href="#CR56" class="usa-link" aria-describedby="CR56">56</a>]. Despite our study showing upward trends in ADR reporting and downward trends in the ratios of HCP-to-consumer ADR reporting in EU countries, it was impossible, again, to determine the individual impact of each initiative on ADR reporting rates.</p>
<p id="Par33">Despite the vaccination due to the COVID-19 pandemic in all countries in 2021 and its related ADR reporting, analysis of the main groups of active substances according to the ATC classification system revealed that the same drug classes remained (just they exchanged the places with each other) during the study period, and vaccine-related ADRs were among the top 5 groups of active substances causing ADRs even from 2012 (just other vaccines) in all the countries except Canada. The study conducted in Germany evaluated all suspected ADR reports from the ADR database of the German Federal Institute for Drugs and Medical Devices containing reports starting from 1978 and found that the most commonly reported top 5 therapeutic groups were antithrombotic agents (B01), antibacterials for systemic use (J01), psycholeptics (N05), psychoanaleptics (N06), and antineoplastic agents (L01) [<a href="#CR57" class="usa-link" aria-describedby="CR57">57</a>]. These therapeutic groups were found to be in the top 10 list of the most frequently reported drugs in our study as well. In the Finnish register-based study on emergency room admissions carried out in the tertiary hospital, the ATC therapeutic subgroups most often involved with ADRs were antithrombotic agents (B01) and antineoplastic agents (L01), followed by analgesics (N02), immunosuppressants (L04), and sex hormones and modulators of the genital system (G03) [<a href="#CR58" class="usa-link" aria-describedby="CR58">58</a>]. Two therapeutic groups, namely B01 and L04, can be seen in the top 10 most frequently reported drugs across all countries in our study. The 2-year data of more than 16,000 individual case safety reports from Israel showed that immunosuppressant drugs (L04 A), antineoplastic agents (L01X), and parathyroid hormones and analogues (H05 A) accounted for around 40% of all ADR reports followed by antithrombotic agents (B01 A) and blood glucose lowering drugs excluding insulin (A10B) (around 5% each) [<a href="#CR59" class="usa-link" aria-describedby="CR59">59</a>]. The therapeutic groups such as L04, L01, and B01 were among the top 5 most frequently reported drugs across all countries in our study.</p>
<p id="Par34">Some limitations of this study have to be acknowledged. First, in the analysis, we included the data of only eight countries that responded. Moreover, the national authorities of some countries could not provide the complete data we asked for. Second, there is a lack of the unified data collection system among the non-EU and EU countries, and this made the analysis complicated. Future analysis should be done involving more countries to gain a better understanding of changes in ADR reporting over time. To prevent future ADRs and consequently to reduce the burden on health care, larger scale studies on the reporting patterns of ADRs by consumers and HCPs are warranted.</p></section><section id="Sec11"><h2 class="pmc_sec_title">Conclusions</h2>
<p id="Par35">Our study shows the significant upward trends in overall ADR reporting not only in the countries that implemented patient ADR reporting systems after the 2012 EU pharmacovigilance legislation but also in the countries that had patient reporting incorporated into the pharmacovigilance systems before 2012. Moreover, significant downward trends in the ratios of HCP-to-consumer ADR reporting were documented for all EU countries, confirming increasing consumer’ involvement in ADR reporting. Further, larger scale studies with the involvement of more countries are needed to better understand the trends in ADR reporting, and multifaceted interventions are warranted to be installed to enhance ADR reporting.</p></section><section id="Sec12"><h2 class="pmc_sec_title">Supplementary Information</h2>
<p>Below is the link to the electronic supplementary material.</p>
<section class="sm xbox font-sm" id="MOESM1"><div class="media p"><div class="caption">
<a href="/articles/instance/12398448/bin/228_2025_3862_MOESM1_ESM.docx" data-ga-action="click_feat_suppl" class="usa-link">Supplementary file1 (DOCX 25 KB)</a><sup> (25.2KB, docx) </sup>
</div></div></section></section><section id="ack1" class="ack"><h2 class="pmc_sec_title">Acknowledgements</h2>
<p>We would like to thank the national competent authorities of all countries that responded and kindly provided the data. Especially we are grateful to Eglė Burbienė, Head of the Pharmacovigilance and Poison Information Unit, State Medicines Control Agency, Lithuania, and Dennis Smits, Data Scientist of the Medicines Evaluation Board, the Netherlands.</p></section><section id="notes1"><h2 class="pmc_sec_title">Author contribution</h2>
<p>E.S. and E.K. contributed to the study conception and design. Material preparation, data collection and analysis were performed by G.M. The first draft of the manuscript was written by G.M. and all authors commented on subsequent versions of the manuscript. All authors read and approved the final version of the manuscript.</p></section><section id="notes2"><h2 class="pmc_sec_title">Data availability</h2>
<p>No datasets were generated or analysed during the current study.</p></section><section id="notes3"><h2 class="pmc_sec_title">Code availability</h2>
<p>The code of this study is available from the corresponding author upon reasonable request.
</p></section><section id="notes4"><h2 class="pmc_sec_title">Declarations</h2>
<section id="FPar1"><h3 class="pmc_sec_title">Ethics approval</h3>
<p id="Par36">Not applicable.</p></section><section id="FPar2"><h3 class="pmc_sec_title">Consent to participate</h3>
<p id="Par37">Not applicable.</p></section><section id="FPar3"><h3 class="pmc_sec_title">Consent for publication</h3>
<p id="Par38">Not applicable.</p></section><section id="FPar4"><h3 class="pmc_sec_title">Conflict of interest</h3>
<p id="Par39">The authors declare no competing interests.</p></section></section><section id="fn-group1" class="fn-group"><h2 class="pmc_sec_title">Footnotes</h2>
<div class="fn-group p font-secondary-light font-sm"><div class="fn p" id="fn1">
<p><strong>Publisher's Note</strong></p>
<p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p>
</div></div></section><section id="Bib1" class="ref-list"><h2 class="pmc_sec_title">References</h2>
<section id="Bib1_sec2"><ul class="ref-list font-sm" style="list-style-type:none">
<li id="CR1">
<span class="label">1.</span><cite>Le Louët H, Pitts PJ (2023) Twenty-first century global ADR management: a need for clarification, redesign, and coordinated action. Ther Innov Regul Sci 57:100–103. 10.1007/s43441-022-00443-8
</cite> [<a href="https://doi.org/10.1007/s43441-022-00443-8" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9368697/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35951160/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Le%20Lou%C3%ABt%20H,%20Pitts%20PJ%20(2023)%20Twenty-first%20century%20global%20ADR%20management:%20a%20need%20for%20clarification,%20redesign,%20and%20coordinated%20action.%20Ther%20Innov%20Regul%20Sci%2057:100%E2%80%93103.%2010.1007/s43441-022-00443-8" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR2">
<span class="label">2.</span><cite>Durand M, Castelli C, Roux-Marson C, Kinowski J, Leguelinel-Blache G (2024) Evaluating the costs of adverse drug events in hospitalized patients: a systematic review. Health Econ Rev 14:11-y. 10.1186/s13561-024-00481-y
</cite> [<a href="https://doi.org/10.1186/s13561-024-00481-y" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10851489/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38329561/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Durand%20M,%20Castelli%20C,%20Roux-Marson%20C,%20Kinowski%20J,%20Leguelinel-Blache%20G%20(2024)%20Evaluating%20the%20costs%20of%20adverse%20drug%20events%20in%20hospitalized%20patients:%20a%20systematic%20review.%20Health%20Econ%20Rev%2014:11-y.%2010.1186/s13561-024-00481-y" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR3">
<span class="label">3.</span><cite>International drug monitoring: the role of national centres. Available online: <a href="https://iris.who.int/bitstream/handle/10665/40968/WH?sequence=1" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://iris.who.int/bitstream/handle/10665/40968/WH?sequence=1</a>. (Accessed 9 June 2024)</cite>
</li>
<li id="CR4">
<span class="label">4.</span><cite>Proposal for a regulation amending, as regards pharmacovigilance of medicinal products for human use. Regulation (EC) No 726/2004. Impact assessment. Available online: <a href="https://eur-lex.europa.eu/legal-content/EN/TXT/PDF/?uri=CELEX:52008SC2671" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://eur-lex.europa.eu/legal-content/EN/TXT/PDF/?uri=CELEX:52008SC2671</a></cite>
</li>
<li id="CR5">
<span class="label">5.</span><cite>Lazarou J, Pomeranz BH, Corey PN (1998) Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA, J Am Med Assoc 279:1200–1205. 10.1001/jama.279.15.1200.Availableonline:doi:10.1001/jama.279.15.1200</cite> [<a href="https://doi.org/10.1001/jama.279.15.1200" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/9555760/" class="usa-link">PubMed</a>]</li>
<li id="CR6">
<span class="label">6.</span><cite>Patel TK, Patel PB (2018) Mortality among patients due to adverse drug reactions that lead to hospitalization: a meta-analysis. Eur J Clin Pharmacol 74:819–832. 10.1007/s00228-018-2441-5
</cite> [<a href="https://doi.org/10.1007/s00228-018-2441-5" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29556685/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Patel%20TK,%20Patel%20PB%20(2018)%20Mortality%20among%20patients%20due%20to%20adverse%20drug%20reactions%20that%20lead%20to%20hospitalization:%20a%20meta-analysis.%20Eur%20J%20Clin%20Pharmacol%2074:819%E2%80%93832.%2010.1007/s00228-018-2441-5" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR7">
<span class="label">7.</span><cite>Bouvy JC, De Bruin ML, Koopmanschap MA (2015) Epidemiology of adverse drug reactions in Europe: a review of recent observational studies. Drug Saf 38:437–453. 10.1007/s40264-015-0281-0
</cite> [<a href="https://doi.org/10.1007/s40264-015-0281-0" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4412588/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25822400/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Bouvy%20JC,%20De%20Bruin%20ML,%20Koopmanschap%20MA%20(2015)%20Epidemiology%20of%20adverse%20drug%20reactions%20in%20Europe:%20a%20review%20of%20recent%20observational%20studies.%20Drug%20Saf%2038:437%E2%80%93453.%2010.1007/s40264-015-0281-0" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR8">
<span class="label">8.</span><cite>Carleton BC, Smith MA (2006) Drug safety: side effects and mistakes or adverse reactions and deadly errors? BCMJ 48:329–333</cite> [<a href="https://scholar.google.com/scholar_lookup?Carleton%20BC,%20Smith%20MA%20(2006)%20Drug%20safety:%20side%20effects%20and%20mistakes%20or%20adverse%20reactions%20and%20deadly%20errors?%20BCMJ%2048:329%E2%80%93333" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR9">
<span class="label">9.</span><cite>Adverse Drug Reactions. Available online: <a href="https://cpnds.ubc.ca/about/" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://cpnds.ubc.ca/about/</a> (Accessed on 5 November 2023).</cite>
</li>
<li id="CR10">
<span class="label">10.</span><cite>Sultana J, Cutroneo P, Trifirò G (2013) Clinical and economic burden of adverse drug reactions. J Pharmacol Pharmacother 4:S73–S77. 10.4103/0976-500X.120957. Available online: <a href="https://www.ncbi.nlm.nih.gov/pubmed/24347988" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://www.ncbi.nlm.nih.gov/pubmed/24347988</a></cite> [<a href="https://doi.org/10.4103/0976-500X.120957" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC3853675/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/24347988/" class="usa-link">PubMed</a>]</li>
<li id="CR11">
<span class="label">11.</span><cite>Ehsani JP, Jackson T, Duckett SJ (2006) The incidence and cost of adverse events in Victorian hospitals 2003–04. Med J Aust 184:551–555. 10.5694/j.1326-5377.2006.tb00378.x. Available online: <a href="https://search.informit.org/documentSummary;res=IELAPA;dn=200606144" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://search.informit.org/documentSummary;res=IELAPA;dn=200606144</a></cite> [<a href="https://doi.org/10.5694/j.1326-5377.2006.tb00378.x" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/16768660/" class="usa-link">PubMed</a>]</li>
<li id="CR12">
<span class="label">12.</span><cite>Osanlou R, Walker L, Hughes DA, Burnside G, Pirmohamed M (2022) Adverse drug reactions, multimorbidity and polypharmacy: a prospective analysis of 1 month of medical admissions. BMJ Open 12. 10.1136/bmjopen-2021-055551</cite> [<a href="https://doi.org/10.1136/bmjopen-2021-055551" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9255409/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35788071/" class="usa-link">PubMed</a>]</li>
<li id="CR13">
<span class="label">13.</span><cite>Safety monitoring of medical products: reporting system for the general public. Available online: <a href="https://apps.who.int/iris/bitstream/handle/10665/336225/9789241503198-eng.pdf?sequence=1&amp;isAllowed=y" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://apps.who.int/iris/bitstream/handle/10665/336225/9789241503198-eng.pdf?sequence=1&amp;isAllowed=y</a>. (Accessed 13 June 2024)</cite>
</li>
<li id="CR14">
<span class="label">14.</span><cite>Herdeiro MT, Figueiras A, Polónia J, Gestal-Otero JJ (2005) Physicians’ attitudes and adverse drug reaction reporting : a case-control study in Portugal. Drug Saf 28:825–833. 10.2165/00002018-200528090-00007
</cite> [<a href="https://doi.org/10.2165/00002018-200528090-00007" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/16119975/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Herdeiro%20MT,%20Figueiras%20A,%20Pol%C3%B3nia%20J,%20Gestal-Otero%20JJ%20(2005)%20Physicians%E2%80%99%20attitudes%20and%20adverse%20drug%20reaction%20reporting%E2%80%AF:%20a%20case-control%20study%20in%20Portugal.%20Drug%20Saf%2028:825%E2%80%93833.%2010.2165/00002018-200528090-00007" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR15">
<span class="label">15.</span><cite>Lopez-Gonzalez E, Herdeiro MT, Figueiras A (2009) Determinants of under-reporting of adverse drug reactions. Drug safety : an international journal of medical toxicology and drug experience 32:19–31. 10.2165/00002018-200932010-00002</cite> [<a href="https://doi.org/10.2165/00002018-200932010-00002" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/19132802/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Lopez-Gonzalez%20E,%20Herdeiro%20MT,%20Figueiras%20A%20(2009)%20Determinants%20of%20under-reporting%20of%20adverse%20drug%20reactions.%20Drug%20safety%E2%80%AF:%20an%20international%20journal%20of%20medical%20toxicology%20and%20drug%20experience%2032:19%E2%80%9331.%2010.2165/00002018-200932010-00002" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR16">
<span class="label">16.</span><cite>Inácio P, Cavaco A, Airaksinen M (2017) The value of patient reporting to the pharmacovigilance system: a systematic review. Br J Clin Pharmacol 83:227–246. 10.1111/bcp.13098
</cite> [<a href="https://doi.org/10.1111/bcp.13098" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5237689/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27558545/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?In%C3%A1cio%20P,%20Cavaco%20A,%20Airaksinen%20M%20(2017)%20The%20value%20of%20patient%20reporting%20to%20the%20pharmacovigilance%20system:%20a%20systematic%20review.%20Br%20J%20Clin%20Pharmacol%2083:227%E2%80%93246.%2010.1111/bcp.13098" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR17">
<span class="label">17.</span><cite>Ancel.la Santos. Direct patient reporting in the European Union. A snapshot of reporting systems in seven member states. <strong>2015</strong> Available online: <a href="https://haiweb.org/wp-content/uploads/2015/09/Direct-Patient-Reporting-in-the-EU.pdf" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://haiweb.org/wp-content/uploads/2015/09/Direct-Patient-Reporting-in-the-EU.pdf</a></cite>
</li>
<li id="CR18">
<span class="label">18.</span><cite>Costa C, Abeijon P, Rodrigues DA, Figueiras A, Herdeiro MT, Torre C (2023) Factors associated with underreporting of adverse drug reactions by patients: a systematic review. Int J Clin Pharm 45:1349–1358. 10.1007/s11096-023-01592-y
</cite> [<a href="https://doi.org/10.1007/s11096-023-01592-y" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10682061/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37247159/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Costa%20C,%20Abeijon%20P,%20Rodrigues%20DA,%20Figueiras%20A,%20Herdeiro%20MT,%20Torre%20C%20(2023)%20Factors%20associated%20with%20underreporting%20of%20adverse%20drug%20reactions%20by%20patients:%20a%20systematic%20review.%20Int%20J%20Clin%20Pharm%2045:1349%E2%80%931358.%2010.1007/s11096-023-01592-y" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR19">
<span class="label">19.</span><cite>Arlett P, Portier G, de Lisa R, Blake K, Wathion N, Dogne J, Spooner A, Raine J, Rasi G (2014) Proactively managing the risk of marketed drugs: experience with the EMA Pharmacovigilance Risk Assessment Committee. Nat Rev Drug Discov 13:395–397. 10.1038/nrd3713-c1
</cite> [<a href="https://doi.org/10.1038/nrd3713-c1" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/24751815/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Arlett%20P,%20Portier%20G,%20de%20Lisa%20R,%20Blake%20K,%20Wathion%20N,%20Dogne%20J,%20Spooner%20A,%20Raine%20J,%20Rasi%20G%20(2014)%20Proactively%20managing%20the%20risk%20of%20marketed%20drugs:%20experience%20with%20the%20EMA%20Pharmacovigilance%20Risk%20Assessment%20Committee.%20Nat%20Rev%20Drug%20Discov%2013:395%E2%80%93397.%2010.1038/nrd3713-c1" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR20">
<span class="label">20.</span><cite>Banovac M, Candore G, Slattery J, Houÿez F, Haerry D, Genov G, Arlett P (2017) Patient reporting in the EU: analysis of EudraVigilance data. Drug Saf 40:629–645. 10.1007/s40264-017-0534-1
</cite> [<a href="https://doi.org/10.1007/s40264-017-0534-1" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28417320/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Banovac%20M,%20Candore%20G,%20Slattery%20J,%20Hou%C3%BFez%20F,%20Haerry%20D,%20Genov%20G,%20Arlett%20P%20(2017)%20Patient%20reporting%20in%20the%20EU:%20analysis%20of%20EudraVigilance%20data.%20Drug%20Saf%2040:629%E2%80%93645.%2010.1007/s40264-017-0534-1" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR21">
<span class="label">21.</span><cite>Margraff F, Bertram D (2014) Adverse drug reaction reporting by patients: an overview of fifty countries. Drug Saf 37:409–419. 10.1007/s40264-014-0162-y
</cite> [<a href="https://doi.org/10.1007/s40264-014-0162-y" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/24748428/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Margraff%20F,%20Bertram%20D%20(2014)%20Adverse%20drug%20reaction%20reporting%20by%20patients:%20an%20overview%20of%20fifty%20countries.%20Drug%20Saf%2037:409%E2%80%93419.%2010.1007/s40264-014-0162-y" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR22">
<span class="label">22.</span><cite>van Hunsel F, Härmark L, Pal S, Olsson S, van Grootheest K (2012) Experiences with adverse drug reaction reporting by patients. Drug Saf 35:45–60. 10.2165/11594320-000000000-00000. Available online: https://link.springer.com/article/10.2165/11594320-000000000-00000</cite> [<a href="https://doi.org/10.2165/11594320-000000000-00000" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/22149419/" class="usa-link">PubMed</a>]</li>
<li id="CR23">
<span class="label">23.</span><cite>Reported side effects following COVID-19 vaccination in Canada. Available online: <a href="https://health-infobase.canada.ca/covid-19/vaccine-safety/" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://health-infobase.canada.ca/covid-19/vaccine-safety/</a> (Accessed on Accessed on 13 February 2025).</cite>
</li>
<li id="CR24">
<span class="label">24.</span><cite>Anatomical Therapeutic Chemical (ATC) Classification. Available online: <a href="https://www.who.int/tools/atc-ddd-toolkit/atc-classification#:~:text=In%20the%20Anatomical%20Therapeutic%20Chemical,groups%20at%20five%20different%20levels" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://www.who.int/tools/atc-ddd-toolkit/atc-classification#:~:text=In%20the%20Anatomical%20Therapeutic%20Chemical,groups%20at%20five%20different%20levels</a> (Accessed on 24 March 2025).</cite>
</li>
<li id="CR25">
<span class="label">25.</span><cite>European Medicines Agency. Serious adverse reaction. Available online: <a href="https://www.ema.europa.eu/en/glossary/serious-adverse-reaction" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://www.ema.europa.eu/en/glossary/serious-adverse-reaction</a>. (Accessed 6 July 2024)</cite>
</li>
<li id="CR26">
<span class="label">26.</span><cite>Howard RL, Avery AJ, Slavenburg S, Royal S, Pipe G, Lucassen P, Pirmohamed M (2007) Which drugs cause preventable admissions to hospital? A systematic review. Br J Clin Pharmacol 63:136–147. 10.1111/j.1365-2125.2006.02698.x
</cite> [<a href="https://doi.org/10.1111/j.1365-2125.2006.02698.x" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC2000562/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/16803468/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Howard%20RL,%20Avery%20AJ,%20Slavenburg%20S,%20Royal%20S,%20Pipe%20G,%20Lucassen%20P,%20Pirmohamed%20M%20(2007)%20Which%20drugs%20cause%20preventable%20admissions%20to%20hospital?%20A%20systematic%20review.%20Br%20J%20Clin%20Pharmacol%2063:136%E2%80%93147.%2010.1111/j.1365-2125.2006.02698.x" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR27">
<span class="label">27.</span><cite>Bäckström M, Mjörndal T, Dahlqvist R (2004) Under-reporting of serious adverse drug reactions in Sweden. Pharmacoepidemiol Drug Saf 13:483–487. 10.1002/pds.962
</cite> [<a href="https://doi.org/10.1002/pds.962" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/15269932/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?B%C3%A4ckstr%C3%B6m%20M,%20Mj%C3%B6rndal%20T,%20Dahlqvist%20R%20(2004)%20Under-reporting%20of%20serious%20adverse%20drug%20reactions%20in%20Sweden.%20Pharmacoepidemiol%20Drug%20Saf%2013:483%E2%80%93487.%2010.1002/pds.962" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR28">
<span class="label">28.</span><cite>García-Abeijon P, Costa C, Taracido M, Herdeiro MT, Torre C, Figueiras A (2023) Factors associated with underreporting of adverse drug reactions by health care professionals: a systematic review update. Drug Saf 46:625–636. 10.1007/s40264-023-01302-7</cite> [<a href="https://doi.org/10.1007/s40264-023-01302-7" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10279571/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37277678/" class="usa-link">PubMed</a>]</li>
<li id="CR29">
<span class="label">29.</span><cite>Inman W, Gent M, Shigmatsu I (1976) Epidemiological issues in reported drug-induced illnesses. McMaster University Library Press Honolulu 17–24</cite>
</li>
<li id="CR30">
<span class="label">30.</span><cite>Sandberg A, Salminen V, Heinonen S, Sivén M (2022) Under-reporting of adverse drug reactions in Finland and healthcare professionals’ perspectives on how to improve reporting. Healthcare (Basel) 10:1015. 10.3390/healthcare10061015. Available online: <a href="https://search.proquest.com/docview/2679715750" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://search.proquest.com/docview/2679715750</a></cite> [<a href="https://doi.org/10.3390/healthcare10061015" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9222550/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35742066/" class="usa-link">PubMed</a>]</li>
<li id="CR31">
<span class="label">31.</span><cite>Li R, Curtis K, Van C, Zaidi TRS, Yeo CY, Arun Kali C, Zaheen M, Therese Moujalli G, Castelino R (2022) Why hospital-based healthcare professionals do not report adverse drug reactions: a mixed methods study using the Theoretical Domains Framework. Eur J Clin Pharmacol 78:1165–1175. 10.1007/s00228-022-03326-x
</cite> [<a href="https://doi.org/10.1007/s00228-022-03326-x" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9043508/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35476123/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Li%20R,%20Curtis%20K,%20Van%20C,%20Zaidi%20TRS,%20Yeo%20CY,%20Arun%20Kali%20C,%20Zaheen%20M,%20Therese%20Moujalli%20G,%20Castelino%20R%20(2022)%20Why%20hospital-based%20healthcare%20professionals%20do%20not%20report%20adverse%20drug%20reactions:%20a%20mixed%20methods%20study%20using%20the%20Theoretical%20Domains%20Framework.%20Eur%20J%20Clin%20Pharmacol%2078:1165%E2%80%931175.%2010.1007/s00228-022-03326-x" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR32">
<span class="label">32.</span><cite>Aung AK, Walker S, Khu YL, Tang MJ, Lee JI, Graudins LV (2022) Adverse drug reaction management in hospital settings: review on practice variations, quality indicators and education focus. Eur J Clin Pharmacol 78:781–791. 10.1007/s00228-022-03287-1. Available online: https://link.springer.com/article/10.1007/s00228-022-03287-1</cite> [<a href="https://doi.org/10.1007/s00228-022-03287-1" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9005418/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35171316/" class="usa-link">PubMed</a>]</li>
<li id="CR33">
<span class="label">33.</span><cite>Hire Rohan C, Kinage Parag J, Gaikwad Nilesh N (2013) Causality assessment in pharmacovigilance: a step towards quality care. Sch J Appl Med Sci 1:386–392, 10.36347/sjams.2013.v01i05.008. Available online: <a href="https://saspublishers.com/media/articles/SJAMS15386-392_w8SI0KZ.pdf" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://saspublishers.com/media/articles/SJAMS15386-392_w8SI0KZ.pdf</a></cite>
</li>
<li id="CR34">
<span class="label">34.</span><cite>Gautron S, Wentzell J, Kanji S, Nguyen T, Kobewka DM, MacDonald E (2018) Characterization of serious adverse drug reactions in hospital to determine potential implications of mandatory reporting. Canadian journal of hospital pharmacy 71:316–323. 10.4212/cjhp.v71i5.2842. Available online: <a href="https://www.ncbi.nlm.nih.gov/pubmed/30401998" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://www.ncbi.nlm.nih.gov/pubmed/30401998</a></cite> [<a href="/articles/PMC6209500/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30401998/" class="usa-link">PubMed</a>]</li>
<li id="CR35">
<span class="label">35.</span><cite>Worakunphanich W, Youngkong S, Suwankesawong W, Anderson C, Thavorncharoensap M (2022) Comparison of patient adverse drug reaction reporting systems in nine selected countries. Int J Environ Res Public Health 19:4447. 10.3390/ijerph19084447. Available online: <a href="https://www.ncbi.nlm.nih.gov/pubmed/35457318" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://www.ncbi.nlm.nih.gov/pubmed/35457318</a></cite> [<a href="https://doi.org/10.3390/ijerph19084447" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9028008/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35457318/" class="usa-link">PubMed</a>]</li>
<li id="CR36">
<span class="label">36.</span><cite>Hussain R, Hassali MA, Ur Rehman A, Muneswarao J, Hashmi F (2020) Physicians’ understanding and practices of pharmacovigilance: qualitative experience from a lower middle-income country. Int J Environ Res Public Health 17:2209. 10.3390/ijerph17072209
</cite> [<a href="https://doi.org/10.3390/ijerph17072209" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7178000/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32218355/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Hussain%20R,%20Hassali%20MA,%20Ur%20Rehman%20A,%20Muneswarao%20J,%20Hashmi%20F%20(2020)%20Physicians%E2%80%99%20understanding%20and%20practices%20of%20pharmacovigilance:%20qualitative%20experience%20from%20a%20lower%20middle-income%20country.%20Int%20J%20Environ%20Res%20Public%20Health%2017:2209.%2010.3390/ijerph17072209" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR37">
<span class="label">37.</span><cite>Elkalmi RM, Hassali MA, Ibrahim MIM, Jamshed SQ, Al-lela O (2014) Community pharmacists’ attitudes, perceptions, and barriers toward adverse drug reaction reporting in Malaysia: a quantitative insight. Journal of Patient Safety 10. Available online: <a href="https://journals.lww.com/journalpatientsafety/fulltext/2014/06000/community_pharmacists__attitudes,_perceptions,_and.1.aspx" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://journals.lww.com/journalpatientsafety/fulltext/2014/06000/community_pharmacists__attitudes,_perceptions,_and.1.aspx</a></cite> [<a href="https://doi.org/10.1097/PTS.0000000000000051" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/24618640/" class="usa-link">PubMed</a>]</li>
<li id="CR38">
<span class="label">38.</span><cite>Hadi MA, Neoh CF, Zin RM, Elrggal ME, Cheema E (2017) Pharmacovigilance: pharmacists’ perspective on spontaneous adverse drug reaction reporting. Integr Pharm Res Pract 6:91–98. 10.2147/IPRP.S105881
</cite> [<a href="https://doi.org/10.2147/IPRP.S105881" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5774327/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29354555/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Hadi%20MA,%20Neoh%20CF,%20Zin%20RM,%20Elrggal%20ME,%20Cheema%20E%20(2017)%20Pharmacovigilance:%20pharmacists%E2%80%99%20perspective%20on%20spontaneous%20adverse%20drug%20reaction%20reporting.%20Integr%20Pharm%20Res%20Pract%206:91%E2%80%9398.%2010.2147/IPRP.S105881" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR39">
<span class="label">39.</span><cite>De Angelis A, Giusti A, Colaceci S, Vellone E, Alvaro R (2015) Nurses’ reporting of suspect adverse drug reactions: a mixed-methods study. Ann Ist Super Sanita 51:277–283. 10.4415/ANN_15_04_06
</cite> [<a href="https://doi.org/10.4415/ANN_15_04_06" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26783213/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?De%20Angelis%20A,%20Giusti%20A,%20Colaceci%20S,%20Vellone%20E,%20Alvaro%20R%20(2015)%20Nurses%E2%80%99%20reporting%20of%20suspect%20adverse%20drug%20reactions:%20a%20mixed-methods%20study.%20Ann%20Ist%20Super%20Sanita%2051:277%E2%80%93283.%2010.4415/ANN_15_04_06" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR40">
<span class="label">40.</span><cite>Karlsson SA, Jacobsson I, Boman MD, Hakkarainen KM, Lövborg H, Hägg S, Jönsson AK (2015) The impact of a changed legislation on reporting of adverse drug reactions in Sweden, with focus on nurses’ reporting. Eur J Clin Pharmacol 71:631–636. 10.1007/s00228-015-1839-6
</cite> [<a href="https://doi.org/10.1007/s00228-015-1839-6" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25845655/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Karlsson%20SA,%20Jacobsson%20I,%20Boman%20MD,%20Hakkarainen%20KM,%20L%C3%B6vborg%20H,%20H%C3%A4gg%20S,%20J%C3%B6nsson%20AK%20(2015)%20The%20impact%20of%20a%20changed%20legislation%20on%20reporting%20of%20adverse%20drug%20reactions%20in%20Sweden,%20with%20focus%20on%20nurses%E2%80%99%20reporting.%20Eur%20J%20Clin%20Pharmacol%2071:631%E2%80%93636.%2010.1007/s00228-015-1839-6" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR41">
<span class="label">41.</span><cite>Hazell L, Shakir SAW (2006) Under-reporting of adverse drug reactions. Drug Saf 29:385–396. 10.2165/00002018-200629050-00003.Availableonline:doi:10.2165/00002018-200629050-00003</cite> [<a href="https://doi.org/10.2165/00002018-200629050-00003" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/16689555/" class="usa-link">PubMed</a>]</li>
<li id="CR42">
<span class="label">42.</span><cite>Blenkinsopp A, Wilkie P, Wang M, Routledge PA (2007) Patient reporting of suspected adverse drug reactions: a review of published literature and international experience. Br J Clin Pharmacol 63:148–156. 10.1111/j.1365-2125.2006.02746.x
</cite> [<a href="https://doi.org/10.1111/j.1365-2125.2006.02746.x" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC2000570/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/17274788/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Blenkinsopp%20A,%20Wilkie%20P,%20Wang%20M,%20Routledge%20PA%20(2007)%20Patient%20reporting%20of%20suspected%20adverse%20drug%20reactions:%20a%20review%20of%20published%20literature%20and%20international%20experience.%20Br%20J%20Clin%20Pharmacol%2063:148%E2%80%93156.%2010.1111/j.1365-2125.2006.02746.x" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR43">
<span class="label">43.</span><cite>Herxheimer Andrew; Crombag Rose; Leonardo Alves Teresa Direct patient reporting of adverse drug reactions. <strong>2010</strong> Available online: <a href="https://consumers.cochrane.org/sites/consumers.cochrane.org/files/uploads/10%20May%202010%20Report%20Direct%20Patient%20Reporting%20of%20ADRs.pdf" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://consumers.cochrane.org/sites/consumers.cochrane.org/files/uploads/10%20May%202010%20Report%20Direct%20Patient%20Reporting%20of%20ADRs.pdf</a>.</cite>
</li>
<li id="CR44">
<span class="label">44.</span><cite>Al Dweik R, Stacey D, Kohen D, Yaya S (2017) Factors affecting patient reporting of adverse drug reactions: a systematic review. Br J Clin Pharmacol 83:875–883. 10.1111/bcp.13159
</cite> [<a href="https://doi.org/10.1111/bcp.13159" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5346870/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27868226/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Al%20Dweik%20R,%20Stacey%20D,%20Kohen%20D,%20Yaya%20S%20(2017)%20Factors%20affecting%20patient%20reporting%20of%20adverse%20drug%20reactions:%20a%20systematic%20review.%20Br%20J%20Clin%20Pharmacol%2083:875%E2%80%93883.%2010.1111/bcp.13159" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR45">
<span class="label">45.</span><cite>Singh A, Bhatt P (2012) Comparative evaluation of adverse drug reaction reporting forms for introduction of a spontaneous generic ADR form. J Pharmacol Pharmacother 3:228–232. 10.4103/0976-500X.99417
</cite> [<a href="https://doi.org/10.4103/0976-500X.99417" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC3487270/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/23129957/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Singh%20A,%20Bhatt%20P%20(2012)%20Comparative%20evaluation%20of%20adverse%20drug%20reaction%20reporting%20forms%20for%20introduction%20of%20a%20spontaneous%20generic%20ADR%20form.%20J%20Pharmacol%20Pharmacother%203:228%E2%80%93232.%2010.4103/0976-500X.99417" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR46">
<span class="label">46.</span><cite>Maharshi V, Nagar P (2017) Comparison of online reporting systems and their compatibility check with respective adverse drug reaction reporting forms. Indian J Pharmacol 49:374–382. 10.4103/ijp.IJP_733_16
</cite> [<a href="https://doi.org/10.4103/ijp.IJP_733_16" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5830848/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29515278/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Maharshi%20V,%20Nagar%20P%20(2017)%20Comparison%20of%20online%20reporting%20systems%20and%20their%20compatibility%20check%20with%20respective%20adverse%20drug%20reaction%20reporting%20forms.%20Indian%20J%20Pharmacol%2049:374%E2%80%93382.%2010.4103/ijp.IJP_733_16" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR47">
<span class="label">47.</span><cite>Pardo-Cabello AJ, Manzano-Gamero V, Luna JDR (2023) Differences in reporting of adverse drug reactions due to COVID-19 vaccines depending on the reporter. Eur J Intern Med 113:104–106. 10.1016/j.ejim.2023.03.020
</cite> [<a href="https://doi.org/10.1016/j.ejim.2023.03.020" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10030326/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36966066/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Pardo-Cabello%20AJ,%20Manzano-Gamero%20V,%20Luna%20JDR%20(2023)%20Differences%20in%20reporting%20of%20adverse%20drug%20reactions%20due%20to%20COVID-19%20vaccines%20depending%20on%20the%20reporter.%20Eur%20J%20Intern%20Med%20113:104%E2%80%93106.%2010.1016/j.ejim.2023.03.020" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR48">
<span class="label">48.</span><cite>Mathieu E, Ritchie H, Ortiz-Ospina E, Roser M, Hasell J, Appel C, Giattino C, Rodés-Guirao L (2021) A global database of COVID-19 vaccinations. Nat Hum Behav 5:947–953. 10.1038/s41562-021-01122-8.Availableonline:doi:10.1038/s41562-021-01122-8</cite> [<a href="https://doi.org/10.1038/s41562-021-01122-8" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33972767/" class="usa-link">PubMed</a>]</li>
<li id="CR49">
<span class="label">49.</span><cite>Total COVID-19 vaccine doses administered. Available online: <a href="https://ourworldindata.org/grapher/cumulative-covid-vaccinations?time=earliest..2021-12-01&amp;facet=none&amp;country=~OWID_WRL" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://ourworldindata.org/grapher/cumulative-covid-vaccinations?time=earliest..2021-12-01&amp;facet=none&amp;country=~OWID_WRL</a> (Accessed on 15–02 2025).</cite>
</li>
<li id="CR50">
<span class="label">50.</span><cite>Durand J, Dogné J, Cohet C, Browne K, Gordillo-Marañón M, Piccolo L, Zaccaria C, Genov G (2023) Safety monitoring of COVID-19 vaccines: perspective from the European Medicines Agency. Clin Pharmacol Ther 113:1223–1234. 10.1002/cpt.2828.Availableonline:doi:10.1002/cpt.2828</cite> [<a href="https://doi.org/10.1002/cpt.2828" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9877988/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36524423/" class="usa-link">PubMed</a>]</li>
<li id="CR51">
<span class="label">51.</span><cite>Napke Ed. A lifetime in safety. Selected articles by Ed Napke. <strong>2010</strong>, 107. <a href="https://view.publitas.com/uppsala-monitoring-centre/a-lifetime-in-safety/page/1" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://view.publitas.com/uppsala-monitoring-centre/a-lifetime-in-safety/page/1</a>. (Accessed 13 July 2024)</cite>
</li>
<li id="CR52">
<span class="label">52.</span><cite>Module 1: Overview of Vanessa’s Law and reporting requirements. Available online: <a href="https://www.canada.ca/en/health-canada/services/drugs-health-products/medeffect-canada/adverse-reaction-reporting/mandatory-hospital-reporting/education/module-1.html" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://www.canada.ca/en/health-canada/services/drugs-health-products/medeffect-canada/adverse-reaction-reporting/mandatory-hospital-reporting/education/module-1.html</a> (Accessed on 13 February 2025).</cite>
</li>
<li id="CR53">
<span class="label">53.</span><cite>Guefack Djiokeng LB, Todkar S, Corbin S, Lavallée M, Pradhan P, Thibault M, Piché M, Méthot J, Bérard A, Gonella JM, Escobar Gimenes FR, Darveau R, Cloutier I, Leclerc J (2024) Impact of Vanessa’s Law on the reporting of serious adverse events: a retrospective study among antiplatelet users in a tertiary-care cardiology centre. CJC Open 6:1527–1533. 10.1016/j.cjco.2024.09.003
</cite> [<a href="https://doi.org/10.1016/j.cjco.2024.09.003" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11681356/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/39735944/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Guefack%20Djiokeng%20LB,%20Todkar%20S,%20Corbin%20S,%20Lavall%C3%A9e%20M,%20Pradhan%20P,%20Thibault%20M,%20Pich%C3%A9%20M,%20M%C3%A9thot%20J,%20B%C3%A9rard%20A,%20Gonella%20JM,%20Escobar%20Gimenes%20FR,%20Darveau%20R,%20Cloutier%20I,%20Leclerc%20J%20(2024)%20Impact%20of%20Vanessa%E2%80%99s%20Law%20on%20the%20reporting%20of%20serious%20adverse%20events:%20a%20retrospective%20study%20among%20antiplatelet%20users%20in%20a%20tertiary-care%20cardiology%20centre.%20CJC%20Open%206:1527%E2%80%931533.%2010.1016/j.cjco.2024.09.003" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR54">
<span class="label">54.</span><cite>Lavallée M, Corbin S, Pradhan P, Guefack LB, Thibault M, Méthot J, Bérard A, Piché M, Gimenes FRE, Darveau R, Cloutier I, Leclerc J (2024) Underreporting of adverse events to health authorities by healthcare professionals: a red flag-raising descriptive study. Int J Qual Health Care 36:mzae109. 10.1093/intqhc/mzae109. 10.1093/intqhc/mzae109</cite> [<a href="https://doi.org/10.1093/intqhc/mzae109" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11879413/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/39604081/" class="usa-link">PubMed</a>]</li>
<li id="CR55">
<span class="label">55.</span><cite>Radecka A, Loughlin L, Foy M, de Ferraz Guimaraes MV, Sarinic VM, Di Giusti MD, Lesicar M, Straus S, Montero D, Pallos J, Ivanovic J, Raine J (2018) Enhancing pharmacovigilance capabilities in the EU regulatory network: the SCOPE joint action. Drug Saf 41:1285–1302. 10.1007/s40264-018-0708-5
</cite> [<a href="https://doi.org/10.1007/s40264-018-0708-5" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6223699/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30128638/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Radecka%20A,%20Loughlin%20L,%20Foy%20M,%20de%20Ferraz%20Guimaraes%20MV,%20Sarinic%20VM,%20Di%20Giusti%20MD,%20Lesicar%20M,%20Straus%20S,%20Montero%20D,%20Pallos%20J,%20Ivanovic%20J,%20Raine%20J%20(2018)%20Enhancing%20pharmacovigilance%20capabilities%20in%20the%20EU%20regulatory%20network:%20the%20SCOPE%20joint%20action.%20Drug%20Saf%2041:1285%E2%80%931302.%2010.1007/s40264-018-0708-5" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR56">
<span class="label">56.</span><cite>Campaign raises awareness of medicines safety in children and pregnancy. Available online: <a href="https://uppsalareports.org/articles/campaign-raises-awareness-of-medicines-safety-in-children-and-pregnancy/" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://uppsalareports.org/articles/campaign-raises-awareness-of-medicines-safety-in-children-and-pregnancy/</a> (Accessed on 15 February 2025).</cite>
</li>
<li id="CR57">
<span class="label">57.</span><cite>Dubrall D, Schmid M, Alešik E, Paeschke N, Stingl J, Sachs B (2018) Frequent adverse drug reactions, and medication groups under suspicion. Dtsch Arztebl Int 115:393–400. 10.3238/arztebl.2018.0393
</cite> [<a href="https://doi.org/10.3238/arztebl.2018.0393" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6041966/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29960607/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Dubrall%20D,%20Schmid%20M,%20Ale%C5%A1ik%20E,%20Paeschke%20N,%20Stingl%20J,%20Sachs%20B%20(2018)%20Frequent%20adverse%20drug%20reactions,%20and%20medication%20groups%20under%20suspicion.%20Dtsch%20Arztebl%20Int%20115:393%E2%80%93400.%2010.3238/arztebl.2018.0393" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR58">
<span class="label">58.</span><cite>Kauppila M, Backman JT, Niemi M, Lapatto-Reiniluoto O (2021) Incidence, preventability, and causality of adverse drug reactions at a university hospital emergency department. Eur J Clin Pharmacol 77:643–650. 10.1007/s00228-020-03043-3
</cite> [<a href="https://doi.org/10.1007/s00228-020-03043-3" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7935812/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33188450/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Kauppila%20M,%20Backman%20JT,%20Niemi%20M,%20Lapatto-Reiniluoto%20O%20(2021)%20Incidence,%20preventability,%20and%20causality%20of%20adverse%20drug%20reactions%20at%20a%20university%20hospital%20emergency%20department.%20Eur%20J%20Clin%20Pharmacol%2077:643%E2%80%93650.%2010.1007/s00228-020-03043-3" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR59">
<span class="label">59.</span><cite>Schwartzberg E, Berkovitch M, Dil Nahlieli D, Nathan J, Gorelik E (2017) Pharmacovigilance in Israel - tools, processes, and actions. Isr J Health Policy Res 6:29–33. 10.1186/s13584-017-0154-3
</cite> [<a href="https://doi.org/10.1186/s13584-017-0154-3" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5537943/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28760141/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Schwartzberg%20E,%20Berkovitch%20M,%20Dil%20Nahlieli%20D,%20Nathan%20J,%20Gorelik%20E%20(2017)%20Pharmacovigilance%20in%20Israel%20-%20tools,%20processes,%20and%20actions.%20Isr%20J%20Health%20Policy%20Res%206:29%E2%80%9333.%2010.1186/s13584-017-0154-3" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
</ul></section></section><section id="_ad93_" lang="en" class="associated-data"><h2 class="pmc_sec_title">Associated Data</h2>
<p class="font-secondary"><em>This section collects any data citations, data availability statements, or supplementary materials included in this article.</em></p>
<section id="_adsm93_" lang="en" class="supplementary-materials"><h3 class="pmc_sec_title">Supplementary Materials</h3>
<section class="sm xbox font-sm" id="db_ds_supplementary-material1_reqid_"><div class="media p"><div class="caption">
<a href="/articles/instance/12398448/bin/228_2025_3862_MOESM1_ESM.docx" data-ga-action="click_feat_suppl" class="usa-link">Supplementary file1 (DOCX 25 KB)</a><sup> (25.2KB, docx) </sup>
</div></div></section></section><section id="_adda93_" lang="en" class="data-availability-statement"><h3 class="pmc_sec_title">Data Availability Statement</h3>
<p>No datasets were generated or analysed during the current study.</p>
<p>The code of this study is available from the corresponding author upon reasonable request.
</p></section></section></section><footer class="p courtesy-note font-secondary font-sm text-center"><hr class="headless">
<p>Articles from European Journal of Clinical Pharmacology are provided here courtesy of <strong>Springer</strong></p></footer></section></article>

                      

                    </main>
                </div>
            </div>
        </div>

        



<!-- Secondary navigation placeholder -->
<div class="pmc-sidenav desktop:grid-col-4 display-flex">
    <section class="pmc-sidenav__container" aria-label="Article resources and navigation">
        <button type="button" class="usa-button pmc-sidenav__container__close usa-button--unstyled">
            <img src="/static/img/usa-icons/close.svg" role="img" alt="Close" />
        </button>
    <div class="display-none desktop:display-block">
       <section class="margin-top-4 desktop:margin-top-0">
              <h2 class="margin-top-0">ACTIONS</h2>
           <ul class="usa-list usa-list--unstyled usa-list--actions">
               
               <li>
                     <a
                             href="https://doi.org/10.1007/s00228-025-03862-2"
                             class="usa-button usa-button--outline width-24 font-xs display-inline-flex flex-align-center flex-justify-start padding-left-1"
                             target="_blank"
                             rel="noreferrer noopener"
                             data-ga-category="actions"
                             data-ga-action="click"
                             data-ga-label="publisher_link_desktop"
                     >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#launch"></use>
                         </svg>
                         <span class="display-inline-flex flex-justify-center flex-1 padding-right-2">View on publisher site</span>
                     </a>
               </li>
               
               
               <li>
                    <a
                            href="pdf/228_2025_Article_3862.pdf"
                            class="usa-button usa-button--outline width-24 display-inline-flex flex-align-center flex-justify-start padding-left-1"
                            data-ga-category="actions"
                            data-ga-action="click"
                            data-ga-label="pdf_download_desktop"
                    >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#file_download"></use>
                        </svg>
                        <span class="display-inline-flex flex-justify-center flex-1">PDF (1.1 MB)</span>
                    </a>
               </li>
               
                
               <li>
                   <button role="button" class="usa-button width-24 citation-dialog-trigger display-inline-flex flex-align-center flex-justify-start padding-left-1"
                        aria-label="Open dialog with citation text in different styles"
                        data-ga-category="actions"
                        data-ga-action="open"
                        data-ga-label="cite_desktop"
                        data-all-citations-url="/resources/citations/12398448/"
                        data-citation-style="nlm"
                        data-download-format-link="/resources/citations/12398448/export/"
                    >
                        <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#format_quote"></use>
                        </svg>
                       <span class="display-inline-flex flex-justify-center flex-1 button-label">Cite</span>
                    </button>
               </li>
                
               <li>

                        <button class="usa-button width-24 collections-dialog-trigger collections-button display-inline-flex flex-align-center flex-justify-start padding-left-1 collections-button-empty"
                              aria-label="Save article in MyNCBI collections."
                              data-ga-category="actions"
                              data-ga-action="click"
                              data-ga-label="collections_button_desktop"
                              data-collections-open-dialog-enabled="false"
                              data-collections-open-dialog-url="https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpmc.ncbi.nlm.nih.gov%2Farticles%2FPMC12398448%2F%23open-collections-dialog"
                              data-in-collections="false">
                            <svg class="usa-icon width-3 height-3 usa-icon--bookmark-full" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-full.svg#icon"></use>
                            </svg>
                            <svg class="usa-icon width-3 height-3 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-empty.svg#icon"></use>
                            </svg>
                            <span class="display-inline-flex flex-justify-center flex-1">Collections</span>
                       </button>
               </li>
               <li class="pmc-permalink">
                    <button
                            type="button"
                            class="usa-button width-24 display-inline-flex flex-align-center flex-justify padding-left-1 shadow-none"
                            aria-label="Show article permalink"
                            aria-expanded="false"
                            aria-haspopup="true"
                            data-ga-category="actions"
                            data-ga-action="open"
                            data-ga-label="permalink_desktop"
                    >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#share"></use>
                        </svg>
                        <span class="display-inline-flex flex-justify-center flex-1 button-label">Permalink</span>
                    </button>
                   

<div class="pmc-permalink__dropdown" hidden>
    <div class="pmc-permalink__dropdown__container">
          <h2 class="usa-modal__heading margin-top-0 margin-bottom-2 text-uppercase font-sans-xs">PERMALINK</h2>
          <div class="pmc-permalink__dropdown__content">
              <input type="text" class="usa-input" value="https://pmc.ncbi.nlm.nih.gov/articles/PMC12398448/" aria-label="Article permalink">
              <button class="usa-button display-inline-flex pmc-permalink__dropdown__copy__btn margin-right-0" title="Copy article permalink" data-ga-category="save_share" data-ga-action="link" data-ga-label="copy_link">
                  <svg class="usa-icon" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#content_copy"></use>
                  </svg>
                  <span class="margin-left-1">Copy</span>
              </button>
          </div>
    </div>
</div>
               </li>
           </ul>
       </section>
     </div>

        <section class="pmc-resources margin-top-6 desktop:margin-top-4" data-page-path="/articles/PMC12398448/">
            <h2 class="margin-top-0">RESOURCES</h2>
            
                <div class="usa-accordion usa-accordion--multiselectable" data-allow-multiple>
                    <h3 class="usa-accordion__heading">
                        <button
                        type="button"
                        class="usa-accordion__button"
                        aria-expanded="false"
                        aria-controls="resources-similar-articles"
                        data-ga-category="resources_accordion"
                        data-ga-action="open_similar_articles"
                        data-ga-label="/articles/PMC12398448/"
                        data-action-open="open_similar_articles"
                        data-action-close="close_similar_articles"
                        >
                            Similar articles
                        </button>
                    </h3>
                    <div
                            id="resources-similar-articles"
                            class="usa-accordion__content usa-prose"
                            
                                data-source-url="/resources/similar-article-links/40528085/"
                            
                    >
                        
                    </div>
                    <h3 class="usa-accordion__heading">
                        <button
                        type="button"
                        class="usa-accordion__button"
                        aria-expanded="false"
                        aria-controls="resources-cited-by-other-articles"
                        data-ga-category="resources_accordion"
                        data-ga-action="open_cited_by"
                        data-ga-label="/articles/PMC12398448/"
                        data-action-open="open_cited_by"
                        data-action-close="close_cited_by"
                        >
                             Cited by other articles
                        </button>
                    </h3>
                    <div
                            id="resources-cited-by-other-articles"
                            class="usa-accordion__content usa-prose"
                            
                                data-source-url="/resources/cited-by-links/40528085/"
                            
                    >
                          
                    </div>
                    
                        <h3 class="usa-accordion__heading">
                            <button
                            type="button"
                            class="usa-accordion__button"
                            aria-expanded="false"
                            aria-controls="resources-links-to-ncbi-databases"
                            data-ga-category="resources_accordion"
                            data-ga-action="open_NCBI_links"
                            data-ga-label="/articles/PMC12398448/"
                            data-action-open="open_NCBI_links"
                            data-action-close="close_NCBI_link"
                            >
                                 Links to NCBI Databases
                            </button>
                        </h3>
                        <div
                                id="resources-links-to-ncbi-databases"
                                class="usa-accordion__content usa-prose"
                                data-source-url="/resources/db-links/12398448/"
                        >
                        </div>
                    
                    
                </div>
            
        </section>


        <section
        class="usa-in-page-nav usa-in-page-nav--wide margin-top-6 desktop:margin-top-4"
        data-title-text="On this page"
        data-title-heading-level="h2"
        data-scroll-offset="0"
        data-root-margin="-10% 0px -80% 0px"
        data-main-content-selector="main"
        data-threshold="1"
        hidden
        ></section>
    </section>
</div>


        

<div class="overlay" role="dialog" aria-label="Citation Dialog" hidden>
    <div class="dialog citation-dialog" aria-hidden="true">
        <div class="display-inline-flex flex-align-center flex-justify width-full margin-bottom-2">
            <h2 class="usa-modal__heading margin-0">Cite</h2>
             <button type="button" class="usa-button usa-button--unstyled close-overlay text-black width-auto"  tabindex="1">
                <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#close"></use>
                </svg>
             </button>
        </div>

        

<div class="citation-text-block">
  <div class="citation-text margin-bottom-2"></div>
  <ul class="usa-list usa-list--unstyled display-inline-flex flex-justify width-full flex-align-center">
      <li>
        <button
          class="usa-button usa-button--unstyled text-no-underline display-flex flex-align-center copy-button dialog-focus"
          data-ga-category="save_share"
          data-ga-action="cite"
          data-ga-label="copy"
          tabindex="2">
            <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                <use xlink:href="/static/img/sprite.svg#content_copy"></use>
            </svg>
            <span>Copy</span>
        </button>
      </li>
      <li>
          <a
              href="#"
              role="button"
              class="usa-button usa-button--unstyled text-no-underline display-flex flex-align-center export-button"
              data-ga-category="save_share"
              data-ga-action="cite"
              data-ga-label="download"
              title="Download a file for external citation management software"
              tabindex="3">
                <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#file_download"></use>
                </svg>
                <span class="display-none mobile-lg:display-inline">Download .nbib</span>
                <span class="display-inline mobile-lg:display-none">.nbib</span>
            </a>
      </li>
      <li>
          

<div class="display-inline-flex flex-align-center">
  <label class="usa-label margin-top-0">Format:</label>
  <select aria-label="Format" class="usa-select citation-style-selector padding-1 margin-top-0 border-0 padding-right-4" tabindex="4" >
    
      <option data-style-url-name="ama"
              value="AMA"
              >
        AMA
      </option>
    
      <option data-style-url-name="apa"
              value="APA"
              >
        APA
      </option>
    
      <option data-style-url-name="mla"
              value="MLA"
              >
        MLA
      </option>
    
      <option data-style-url-name="nlm"
              value="NLM"
              selected="selected">
        NLM
      </option>
    
  </select>
</div>
      </li>
  </ul>
</div>
    </div>
</div>

        <div class="overlay" role="dialog" hidden>
  <div id="collections-action-dialog" class="dialog collections-dialog" aria-hidden="true">
   <div class="display-inline-flex flex-align-center flex-justify width-full margin-bottom-2">
        <h2 class="usa-modal__heading margin-0">Add to Collections</h2>
    </div>
    <div class="collections-action-panel action-panel">
      


<form id="collections-action-dialog-form"
      class="usa-form maxw-full collections-action-panel-form action-panel-content action-form action-panel-smaller-selectors"
      data-existing-collections-url="/list-existing-collections/"
      data-add-to-existing-collection-url="/add-to-existing-collection/"
      data-create-and-add-to-new-collection-url="/create-and-add-to-new-collection/"
      data-myncbi-max-collection-name-length="100"
      data-collections-root-url="https://www.ncbi.nlm.nih.gov/myncbi/collections/">

    <input type="hidden" name="csrfmiddlewaretoken" value="YqOXTWQZabHUf9fsfQmDsLaJQYmRDZs2SqCoNuukHoWRnf53eYgwd1DjSEumLTyB">

    <fieldset class="usa-fieldset margin-bottom-2">
        <div class="usa-radio">
            <input type="radio"
            id="collections-action-dialog-new"
            class="usa-radio__input usa-radio__input--tile collections-new  margin-top-0"
            name="collections"
            value="new"
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="collections_radio_new" />
            <label class="usa-radio__label" for="collections-action-dialog-new">Create a new collection</label>
        </div>
        <div class="usa-radio">
            <input type="radio"
            id="collections-action-dialog-existing"
            class="usa-radio__input usa-radio__input--tile collections-existing"
            name="collections"
            value="existing"
            checked="true"
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="collections_radio_existing" />
            <label class="usa-radio__label" for="collections-action-dialog-existing">Add to an existing collection</label>
        </div>
    </fieldset>

    <fieldset class="usa-fieldset margin-bottom-2">
        <div class="action-panel-control-wrap new-collections-controls">
           <label for="collections-action-dialog-add-to-new" class="usa-label margin-top-0">
                Name your collection
               <abbr title="required" class="usa-hint usa-hint--required text-no-underline">*</abbr>
          </label>
          <input
            type="text"
            name="add-to-new-collection"
            id="collections-action-dialog-add-to-new"
            class="usa-input collections-action-add-to-new"
            pattern="[^&quot;&amp;=&lt;&gt;/]*" title="The following characters are not allowed in the Name field: &quot;&amp;=&lt;&gt;/"
            maxlength=""
            data-ga-category="collections_button"
            data-ga-action="create_collection"
            data-ga-label="non_favorties_collection"
            required
          />
        </div>
        <div class="action-panel-control-wrap existing-collections-controls">
             <label for="collections-action-dialog-add-to-existing" class="usa-label margin-top-0">
                Choose a collection
              </label>
              <select id="collections-action-dialog-add-to-existing"
                      class="usa-select collections-action-add-to-existing"
                      data-ga-category="collections_button"
                      data-ga-action="select_collection"
                      data-ga-label="($('.collections-action-add-to-existing').val() === 'Favorites') ? 'Favorites' : 'non_favorites_collection'">
              </select>
              <div class="collections-retry-load-on-error usa-input-error-message selection-validation-message">
                Unable to load your collection due to an error<br>
                <a href="#">Please try again</a>
              </div>
        </div>
    </fieldset>

    <div class="display-inline-flex">
        <button class="usa-button margin-top-0 action-panel-submit"
            type="submit"
            data-loading-label="Adding..."
            data-pinger-ignore
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="add">
          Add
        </button>
        <button class="usa-button usa-button--outline margin-top-0 action-panel-cancel"
                aria-label="Close 'Add to Collections' panel"
                ref="linksrc=close_collections_panel"
                data-ga-category="collections_button"
                data-ga-action="click"
                data-ga-label="cancel">
          Cancel
        </button>
    </div>
</form>
    </div>
  </div>
</div>

        

      </div>
    </div>
  </div>



        
    
    

<footer class="ncbi-footer ncbi-dark-background " >
    
        <div class="ncbi-footer__icon-section">
            <div class="ncbi-footer__social-header">
                Follow NCBI
            </div>

            <div class="grid-container ncbi-footer__ncbi-social-icons-container">
                
                    <a href="https://twitter.com/ncbi"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="40"
                             height="40"
                             viewBox="0 0 40 40"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="m6.067 8 10.81 13.9L6 33.2h4.2l8.4-9.1 7.068 9.1H34L22.8 18.5 31.9 8h-3.5l-7.7 8.4L14.401 8H6.067Zm3.6 1.734h3.266l16.8 21.732H26.57L9.668 9.734Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on X (formerly known as Twitter)</span>
                    </a>
                

                
                    <a href="https://www.facebook.com/ncbi.nlm"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="16"
                             height="29"
                             focusable="false"
                             aria-hidden="true"
                             viewBox="0 0 16 29"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg">
                            <path d="M3.8809 21.4002C3.8809 19.0932 3.8809 16.7876 3.8809 14.478C3.8809 14.2117 3.80103 14.1452 3.54278 14.1492C2.53372 14.1638 1.52334 14.1492 0.514288 14.1598C0.302626 14.1598 0.248047 14.0972 0.248047 13.8936C0.256034 12.4585 0.256034 11.0239 0.248047 9.58978C0.248047 9.37013 0.302626 9.30224 0.528931 9.3049C1.53798 9.31688 2.54837 9.3049 3.55742 9.31555C3.80103 9.31555 3.8809 9.26097 3.87957 9.00272C3.87158 8.00565 3.85428 7.00592 3.90753 6.00884C3.97142 4.83339 4.31487 3.73115 5.04437 2.78467C5.93095 1.63318 7.15699 1.09005 8.56141 0.967577C10.5582 0.79319 12.555 0.982221 14.5518 0.927641C14.7102 0.927641 14.7462 0.99287 14.7449 1.13664C14.7449 2.581 14.7449 4.02668 14.7449 5.47104C14.7449 5.67604 14.6517 5.68669 14.4946 5.68669C13.4523 5.68669 12.4113 5.68669 11.3703 5.68669C10.3506 5.68669 9.92057 6.10868 9.90593 7.13904C9.89661 7.7647 9.91525 8.39303 9.89794 9.01869C9.88995 9.26364 9.96583 9.31822 10.2015 9.31688C11.7204 9.30623 13.2393 9.31688 14.7595 9.3049C15.0257 9.3049 15.0723 9.3728 15.0444 9.62439C14.89 10.9849 14.7515 12.3467 14.6144 13.7085C14.5691 14.1571 14.5785 14.1585 14.1458 14.1585C12.8386 14.1585 11.5313 14.1665 10.2254 14.1518C9.95119 14.1518 9.89794 14.2317 9.89794 14.4899C9.90593 19.0799 9.89794 23.6752 9.91125 28.2612C9.91125 28.5674 9.8407 28.646 9.53186 28.6433C7.77866 28.6273 6.02414 28.6366 4.27094 28.634C3.82499 28.634 3.87158 28.6992 3.87158 28.22C3.87602 25.9472 3.87913 23.6739 3.8809 21.4002Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on Facebook</span>
                    </a>
                

                
                    <a href="https://www.linkedin.com/company/ncbinlm"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="25"
                             height="23"
                             viewBox="0 0 26 24"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M14.6983 9.98423C15.6302 9.24808 16.5926 8.74754 17.6762 8.51991C19.673 8.09126 21.554 8.30824 23.1262 9.7526C24.2351 10.7723 24.7529 12.1115 25.0165 13.5612C25.1486 14.3363 25.2105 15.1218 25.2015 15.9081C25.2015 18.3043 25.2015 20.6898 25.2082 23.0806C25.2082 23.3468 25.1549 23.444 24.8621 23.4414C23.1297 23.4272 21.3992 23.4272 19.6704 23.4414C19.4041 23.4414 19.3429 23.3588 19.3442 23.1019C19.3535 20.5194 19.3442 17.9368 19.3442 15.3543C19.3442 14.0005 18.3258 12.9448 17.0266 12.9488C15.7273 12.9528 14.6983 14.0071 14.6983 15.361C14.6983 17.9328 14.6917 20.5047 14.6983 23.0753C14.6983 23.3708 14.6198 23.444 14.3296 23.4427C12.6185 23.4294 10.9079 23.4294 9.19779 23.4427C8.93155 23.4427 8.86099 23.3735 8.86232 23.1086C8.8783 19.7619 8.88628 16.4144 8.88628 13.066C8.88628 11.5688 8.87874 10.0708 8.86365 8.57182C8.86365 8.3575 8.90758 8.27896 9.14054 8.28029C10.9048 8.29094 12.6687 8.29094 14.4321 8.28029C14.6464 8.28029 14.6983 8.34818 14.6983 8.54653C14.6903 9.00047 14.6983 9.45441 14.6983 9.98423Z">
                            </path>
                            <path d="M6.55316 15.8443C6.55316 18.2564 6.55316 20.6699 6.55316 23.082C6.55316 23.3629 6.48127 23.4388 6.19906 23.4374C4.47737 23.4241 2.75568 23.4241 1.03399 23.4374C0.767751 23.4374 0.69986 23.3629 0.701191 23.1006C0.709178 18.2648 0.709178 13.4281 0.701191 8.59053C0.701191 8.34026 0.765089 8.27237 1.01669 8.2737C2.74991 8.28435 4.48048 8.28435 6.20838 8.2737C6.47462 8.2737 6.5465 8.33627 6.54517 8.6065C6.54783 11.0186 6.55316 13.4308 6.55316 15.8443Z">
                            </path>
                            <path d="M3.65878 0.243898C5.36804 0.243898 6.58743 1.45529 6.58743 3.1406C6.58743 4.75801 5.32145 5.95742 3.60819 5.96807C3.22177 5.97614 2.83768 5.90639 2.47877 5.76299C2.11985 5.61959 1.79344 5.40546 1.51897 5.13334C1.24449 4.86123 1.02755 4.53668 0.881058 4.17902C0.734563 3.82136 0.661505 3.43788 0.666231 3.05141C0.67555 1.42601 1.9362 0.242566 3.65878 0.243898Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on LinkedIn</span>
                    </a>
                

                
                    <a href="https://github.com/ncbi"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="28"
                             height="27"
                             viewBox="0 0 28 28"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M16.7228 20.6334C17.5057 20.5527 18.2786 20.3944 19.0301 20.1608C21.3108 19.4193 22.5822 17.8259 22.963 15.4909C23.1228 14.5112 23.1814 13.5287 22.9883 12.5437C22.8106 11.6423 22.4013 10.8028 21.8007 10.1076C21.7526 10.0605 21.7197 10 21.7064 9.934C21.6931 9.86799 21.7 9.79952 21.7262 9.73748C22.0856 8.6206 21.9711 7.51969 21.601 6.42677C21.582 6.3497 21.5345 6.2827 21.468 6.23923C21.4016 6.19577 21.3211 6.17906 21.2429 6.19248C20.7329 6.21649 20.2313 6.33051 19.7611 6.52928C19.1103 6.7908 18.4899 7.12198 17.9104 7.51703C17.84 7.56996 17.7581 7.60551 17.6713 7.62078C17.5846 7.63605 17.4954 7.6306 17.4112 7.60489C15.2596 7.05882 13.0054 7.06203 10.8554 7.61421C10.7806 7.63586 10.7018 7.63967 10.6253 7.62534C10.5487 7.611 10.4766 7.57892 10.4148 7.53167C9.64788 7.03247 8.85171 6.58918 7.96368 6.33359C7.65781 6.24338 7.34123 6.19458 7.02239 6.18849C6.94879 6.17986 6.87462 6.19893 6.81432 6.242C6.75402 6.28507 6.71191 6.34904 6.69621 6.42145C6.32342 7.51437 6.2209 8.61527 6.56307 9.73348C6.59635 9.84264 6.64694 9.93316 6.54177 10.0516C5.47666 11.2604 5.09988 12.6834 5.19574 14.2676C5.2663 15.4244 5.46201 16.5466 6.01454 17.5769C6.84399 19.1171 8.21664 19.9119 9.85158 20.3352C10.3938 20.4706 10.9444 20.5698 11.4998 20.632C11.5384 20.7492 11.4506 20.7798 11.408 20.8291C11.1734 21.1179 10.9894 21.4441 10.8634 21.7942C10.7622 22.0458 10.8315 22.4039 10.6065 22.5516C10.263 22.7766 9.83827 22.8485 9.42421 22.8871C8.17936 23.0056 7.26471 22.4877 6.6283 21.4348C6.25552 20.8184 5.76956 20.3325 5.08523 20.0663C4.76981 19.9325 4.42139 19.8967 4.08537 19.9638C3.7898 20.029 3.73788 20.1901 3.93891 20.4111C4.03639 20.5234 4.14989 20.6207 4.27575 20.6999C4.9796 21.1318 5.51717 21.7884 5.80152 22.5636C6.37002 23.9973 7.48039 24.5697 8.93825 24.6323C9.43741 24.6575 9.93768 24.615 10.4254 24.5058C10.5892 24.4672 10.6531 24.4872 10.6517 24.6762C10.6451 25.4936 10.6637 26.3123 10.6517 27.131C10.6517 27.6635 10.1684 27.9297 9.58663 27.7393C8.17396 27.2671 6.84977 26.5631 5.66838 25.656C2.59555 23.2891 0.720966 20.1861 0.217704 16.3376C-0.357453 11.9127 0.911353 8.00824 3.98551 4.73881C6.11909 2.42656 8.99932 0.939975 12.1203 0.540191C16.5351 -0.0601815 20.4347 1.14323 23.7232 4.16373C26.2449 6.47869 27.724 9.37672 28.1048 12.7726C28.5828 17.0325 27.3686 20.7945 24.4768 23.9827C22.9762 25.6323 21.0956 26.8908 18.9982 27.6488C18.8783 27.6927 18.7585 27.738 18.636 27.7726C18.0356 27.9404 17.6189 27.6395 17.6189 27.0098C17.6189 25.7452 17.6308 24.4806 17.6295 23.2159C17.6329 22.9506 17.6128 22.6856 17.5696 22.4238C17.4325 21.6664 17.3419 21.484 16.7228 20.6334Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on GitHub</span>
                    </a>
                

                
                    <a href="https://ncbiinsights.ncbi.nlm.nih.gov/"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="26"
                             height="26"
                             viewBox="0 0 27 27"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M23.7778 26.4574C23.1354 26.3913 22.0856 26.8024 21.636 26.3087C21.212 25.8444 21.4359 24.8111 21.324 24.0347C19.9933 14.8323 14.8727 8.80132 6.09057 5.85008C4.37689 5.28406 2.58381 4.99533 0.779072 4.99481C0.202773 4.99481 -0.0229751 4.83146 0.00455514 4.21479C0.0660406 3.08627 0.0660406 1.95525 0.00455514 0.826734C-0.0413285 0.0815827 0.259669 -0.0193618 0.896534 0.00266238C6.96236 0.222904 12.3693 2.24179 16.9889 6.16209C22.9794 11.2478 26.1271 17.7688 26.4372 25.648C26.4629 26.294 26.3179 26.5271 25.6609 26.4684C25.0827 26.417 24.4991 26.4574 23.7778 26.4574Z">
                            </path>
                            <path d="M14.8265 26.441C14.0924 26.441 13.2371 26.6795 12.6626 26.3786C12.0092 26.0372 12.3781 25.0644 12.246 24.378C11.1154 18.5324 6.6849 14.5497 0.74755 14.1001C0.217135 14.0615 -0.0104482 13.9422 0.0134113 13.3659C0.0519536 12.1454 0.0482829 10.9213 0.0134113 9.69524C-0.00127145 9.14464 0.196946 9.03268 0.703502 9.04736C9.21217 9.27128 16.5994 16.2511 17.2804 24.7231C17.418 26.4446 17.418 26.4446 15.6579 26.4446H14.832L14.8265 26.441Z">
                            </path>
                            <path d="M3.58928 26.4555C2.64447 26.4618 1.73584 26.0925 1.06329 25.4289C0.39073 24.7653 0.00933763 23.8617 0.0030097 22.9169C-0.00331824 21.9721 0.365937 21.0635 1.02954 20.3909C1.69315 19.7184 2.59675 19.337 3.54156 19.3306C4.48637 19.3243 5.39499 19.6936 6.06755 20.3572C6.7401 21.0208 7.1215 21.9244 7.12782 22.8692C7.13415 23.814 6.7649 24.7226 6.10129 25.3952C5.43768 26.0677 4.53409 26.4491 3.58928 26.4555Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI RSS feed</span>
                    </a>
                
            </div>
        </div>
    

    <div data-testid="gridContainer"
         class="grid-container ncbi-footer__container">
        <div class="grid-row ncbi-footer__main-content-container"
             data-testid="grid">
            
                <div class="ncbi-footer__column">
                    
                        <p class="ncbi-footer__circled-icons-heading">
                            Connect with NLM
                        </p>
                    

                    <div class="ncbi-footer__circled-icons-list">
                        
                            <a href=https://twitter.com/nlm_nih class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="32"
                                     height="32"
                                     viewBox="0 0 40 40"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="m6.067 8 10.81 13.9L6 33.2h4.2l8.4-9.1 7.068 9.1H34L22.8 18.5 31.9 8h-3.5l-7.7 8.4L14.401 8H6.067Zm3.6 1.734h3.266l16.8 21.732H26.57L9.668 9.734Z">
                                    </path>
                                </svg>
                                <span class="usa-sr-only">NLM on X (formerly known as Twitter)</span>
                            </a>
                        

                        
                            <a href=https://www.facebook.com/nationallibraryofmedicine class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="13"
                                     height="24"
                                     viewBox="0 0 13 24"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="M4.11371 23.1369C4.11371 23.082 4.11371 23.0294 4.11371 22.9745V12.9411H0.817305C0.6709 12.9411 0.670898 12.9411 0.670898 12.8016C0.670898 11.564 0.670898 10.3287 0.670898 9.09341C0.670898 8.97903 0.705213 8.95158 0.815017 8.95158C1.8673 8.95158 2.91959 8.95158 3.97417 8.95158H4.12057V8.83263C4.12057 7.8055 4.12057 6.7738 4.12057 5.74897C4.1264 4.92595 4.31387 4.11437 4.66959 3.37217C5.12916 2.38246 5.94651 1.60353 6.95717 1.1921C7.64827 0.905008 8.3913 0.764035 9.13953 0.778051C10.0019 0.791777 10.8644 0.830666 11.7268 0.860404C11.8869 0.860404 12.047 0.894717 12.2072 0.90158C12.2964 0.90158 12.3261 0.940469 12.3261 1.02968C12.3261 1.5421 12.3261 2.05452 12.3261 2.56465C12.3261 3.16857 12.3261 3.7725 12.3261 4.37642C12.3261 4.48165 12.2964 4.51367 12.1912 4.51138C11.5369 4.51138 10.8804 4.51138 10.2261 4.51138C9.92772 4.51814 9.63058 4.5526 9.33855 4.61433C9.08125 4.6617 8.84537 4.78881 8.66431 4.97766C8.48326 5.16652 8.3662 5.40755 8.32972 5.66661C8.28476 5.89271 8.26027 6.1224 8.25652 6.35289C8.25652 7.19014 8.25652 8.02969 8.25652 8.86923C8.25652 8.89439 8.25652 8.91955 8.25652 8.95615H12.0219C12.1797 8.95615 12.182 8.95616 12.1614 9.10714C12.0768 9.76596 11.9876 10.4248 11.9029 11.0813C11.8312 11.6319 11.7626 12.1824 11.697 12.733C11.6719 12.9434 11.6787 12.9434 11.4683 12.9434H8.26338V22.899C8.26338 22.979 8.26338 23.0591 8.26338 23.1392L4.11371 23.1369Z">
                                    </path>
                                </svg>
                                <span class="usa-sr-only">NLM on Facebook</span>
                            </a>
                        

                        
                            <a href=https://www.youtube.com/user/NLMNIH class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="21"
                                     height="15"
                                     viewBox="0 0 21 15"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="M19.2561 1.47914C18.9016 1.15888 18.5699 0.957569 17.2271 0.834039C15.5503 0.678484 13.2787 0.655608 11.563 0.65332H9.43556C7.71987 0.65332 5.4483 0.678484 3.77151 0.834039C2.43098 0.957569 2.097 1.15888 1.74242 1.47914C0.813665 2.32097 0.619221 4.62685 0.598633 6.89384C0.598633 7.31781 0.598633 7.74101 0.598633 8.16345C0.626084 10.4121 0.827391 12.686 1.74242 13.521C2.097 13.8412 2.4287 14.0425 3.77151 14.1661C5.4483 14.3216 7.71987 14.3445 9.43556 14.3468H11.563C13.2787 14.3468 15.5503 14.3216 17.2271 14.1661C18.5676 14.0425 18.9016 13.8412 19.2561 13.521C20.1712 12.6929 20.3725 10.451 20.3999 8.22064C20.3999 7.74025 20.3999 7.25986 20.3999 6.77946C20.3725 4.54907 20.1689 2.30724 19.2561 1.47914ZM8.55942 10.5311V4.65201L13.5601 7.50005L8.55942 10.5311Z"
                                          fill="white" />
                                </svg>
                                <span class="usa-sr-only">NLM on YouTube</span>
                            </a>
                        
                    </div>
                </div>
            

            
                <address class="ncbi-footer__address ncbi-footer__column">
                    
        <p>
            <a class="usa-link usa-link--external"
            href="https://www.google.com/maps/place/8600+Rockville+Pike,+Bethesda,+MD+20894/%4038.9959508,
            -77.101021,17z/data%3D!3m1!4b1!4m5!3m4!1s0x89b7c95e25765ddb%3A0x19156f88b27635b8!8m2!3d38.9959508!
            4d-77.0988323"
            rel="noopener noreferrer" target="_blank">National Library of Medicine
            <br/> 8600 Rockville Pike<br/> Bethesda, MD 20894</a>
        </p>
    
                </address>
            

            
                <ul class="usa-list usa-list--unstyled ncbi-footer__vertical-list ncbi-footer__column">
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nlm.nih.gov/web_policies.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Web Policies
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nih.gov/institutes-nih/nih-office-director/office-communications-public-liaison/freedom-information-act-office" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            FOIA
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.hhs.gov/vulnerability-disclosure-policy/index.html" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
        

        
            HHS Vulnerability Disclosure
        

        
    </a>


                        </li>
                    
                </ul>
            

            
                <ul class="usa-list usa-list--unstyled ncbi-footer__vertical-list ncbi-footer__column">
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://support.nlm.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Help
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nlm.nih.gov/accessibility.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Accessibility
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nlm.nih.gov/careers/careers.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Careers
        

        
    </a>


                        </li>
                    
                </ul>
            
        </div>

        
            <div class="grid-row grid-col-12" data-testid="grid">
                <ul class="ncbi-footer__bottom-links-list">
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.nlm.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            NLM
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            NIH
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.hhs.gov/" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
        

        
            HHS
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.usa.gov/" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
        

        
            USA.gov
        

        
    </a>


                        </li>
                    
                </ul>
            </div>
        
    </div>
</footer>

    


        
        
    
  <script  type="text/javascript" src="https://cdn.ncbi.nlm.nih.gov/core/pinger/pinger.js"> </script>


    
        

<button class="back-to-top" data-ga-category="pagination" data-ga-action="back_to_top">
    <label>Back to Top</label>
    <svg class="usa-icon order-0" aria-hidden="true" focusable="false" role="img">
        <use xlink:href="/static/img/sprite.svg#arrow_upward"></use>
    </svg>
</button>
    


        
    
    
    
        
    <script type="application/javascript">
    window.ncbi = window.ncbi || {};
    window.ncbi.pmc = window.ncbi.pmc || {};
    window.ncbi.pmc.options = {
        logLevel: 'INFO',
        
        staticEndpoint: '/static/',
        
        citeCookieName: 'pmc-cf',
    };
</script>
    <script type="module" crossorigin="" src="/static/assets/base-B7-tgZZA.js"></script>
    
    <script type="text/javascript" src="https://cdn.ncbi.nlm.nih.gov/core/jquery/jquery-3.6.0.min.js">&#xA0;</script>
    <script type="text/javascript">
        jQuery.getScript("https://cdn.ncbi.nlm.nih.gov/core/alerts/alerts.js", function () {
            galert(['div.nav_and_browser', 'div.header', '#universal_header', '.usa-banner', 'body > *:nth-child(1)'])
        });
    </script>


    <script type="text/javascript">var exports = {};</script>
     <script src="/static/CACHE/js/output.13b077bc3ffd.js"></script>

    <script type="module" crossorigin="" src="/static/assets/article-BLbQGH8u.js"></script>
    
    

    </body>
</html>
